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Abstract 
Drug development is a highly resource intensive process that uses large 
numbers of animals for assessing the safety and efficacy of drugs prior to 
clinical testing. Improving the efficiency of drug development in terms of 
financial expenditure and number of animals used is therefore of utmost 
concern, not only to industry, but also to animal welfare organisations such as 
the NC3Rs. Poor efficiency in drug development largely stems from drug 
attrition, particularly attrition in the latter stages of the testing due to the large 
amount of resources expended at the point of failure. It is therefore imperative 
that deleterious off-target effects are identified as early as possible. However, 
typically, identification of seizure as a side-effect of drugs is performed in the 
later stages of development due to the highly intensive and low-throughput 
nature of seizure assays. At which point, if a compound fails, a large amount of 
resources have been squandered. There therefore exists a need for high-
throughput and relatively inexpensive seizure liability assays that can be used 
early in drug development to prevent compounds destined for failure 
undergoing unnecessary resource intensive testing.    
In this thesis we propose a refined approach using non-invasive imaging 
techniques in non-protected life stage zebrafish as a method for the detection of 
seizurogenic compounds early in drug development. In addition, we highlight its 
utility for elucidating the pharmacodynamics of compounds. In this study, a 
transgenic zebrafish line containing a GCaMP6s calcium sensor under the 
control of the pan-neuronal promoter elavl3 was used for functional profiling of 
compounds with varied pharmacologies. Light sheet microscopy was used to 
record fluorescent activity in three spatial dimensions over time (4-dimensions) 
from the zebrafish brain after exposure to forty-three different compounds with 
varied pharmacodynamics and seizure liability profiles. Hierarchical clustering 
was employed in order to assess if compounds with seizurogenic activity or 
similar pharmacodynamics elicited specific functional brain activity. It was found 
that compounds with dopaminergic and serotonergic mechanisms of action 
elicited highly specific and similar brain activity patterns and that non-
seizurogenic drugs also clustered separately from seizurogenic ones. 
Subsequent analyses, focussed on the utilisation of machine learning 
techniques, developing a model that could be used to discriminate between 
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compounds with and without potentially seizurogenic effects. It is clear, from the 
analyses presented here, that drugs do in fact elicit specific brain patterns in 
zebrafish and that these brain patterns are effectively detected using light sheet 
microscopy. This system is highly applicable for use within the drug industry 
and even in its relatively preliminary stages provided an accurate method of 
discriminating between compounds based on their physiological effects in 
zebrafish. 
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Chapter One: Introduction 
The drug industry currently relies heavily on mammalian models for neurotropic 
drug profiling. Drug profiling is used to better understand drug effects as well as 
for assessing safety. The main approaches used for assessing the effects of 
compounds on the brain in vivo are pharmaco-EEG studies in mammals, which 
tend to have poor coverage of the brain and involve stressful and invasive 
procedures on rodents (1). In this thesis I outline the utility of zebrafish larvae as 
an alternative approach for profiling compounds for both assessing drug effects, 
in terms of pharmacodynamics, and also for safety testing. Zebrafish larvae 
have a number of advantages over mammalians models, including high 
reproductive rate and a transparent epidermis making them uniquely suited for 
high throughput imaging assays (2). Zebrafish are a quick and easy organism to 
cultivate and relatively easy to genetically engineer, compared with to their 
mammalian counterparts (3). Moreover, due to their small brain volume, 
zebrafish larvae are particularly suited to whole brain functional imaging making 
them an ideal model organism for studying functional connectivity, as the entire 
brain can imaged in a relatively short timeframe (~1.8 seconds using light sheet 
microscopy (4).  
In terms of safety assessment, this thesis focuses on identifying compounds 
with potentially seizurogenic effects, a highly dangerous side effect of a number 
of neurotropic drugs. Currently seizure liability is performed late in drug 
development because seizure liability assays are highly resource intensive. As 
such, if compounds fail seizure liability testing, a large amount of resources are 
wasted, as said compound has already undergone a large battery of tests. It is 
therefore imperative that a relatively quick and inexpensive assay is developed 
so that seizurogenic compounds can be identified earlier on in drug 
development. The advantages conferred by using larval zebrafish make them 
an ideal candidates for just such a low resources and high throughput assay.   
 It should be noted, however, that the techniques described could be applied in 
a variety of drug profiling scenarios and are not necessarily solely applicable to 
the seizurogenic potential of compounds. 
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In order to understand the potential contribution of zebrafish as a model 
organism, to the area of neurotropic drug screening, it is necessary to start by 
giving an appraisal of the use of mammalian systems for drug profiling and 
discovery. 
 
Mammalian models for classifying the effects of pharmacological agents on 
human neurophysiology. 
 
Traditional approaches to assessing the effects of drugs on human brain 
function are based, to a large extent, around performing pharmaco-
electroencephalography (p-EEG) on mammals. It is clear from the numerous 
studies that have used this approach, that drugs can elicit specific and 
measurable changes in the electrical activity of the brain. As such, it is possible 
to use EEG data to elucidate the properties of drugs (5). In addition to the 
classification of drugs, p-EEG has been used to better understand the 
relationship between pharmacokinetics and pharmacodynamics. For example, 
by looking at the effect of a range of benzodiazepines on EEG power spectra it 
was observed that there is a strong correlation between GABAA receptor affinity 
(as measured in vitro) and changes in the amplitude of β frequency bands in 
vivo (6).  
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Multi-electrode EEGs are a commonly used tool and allow recording from 
multiple brain areas simultaneously (7). The information provided using these 
techniques can be used to assess the effect of drugs on brain activity extracted 
from different brain 
regions. For example, 
multi-electrode 
epicranial EEG 
recordings taken from 
freely behaving mice 
have demonstrated that 
cognition enhancing 
compounds, with varied 
pharmacologies, have 
distinctive effects on 
brain activity. When 
cognition enhancing 
compounds were 
clustered alongside a 
plethora of 
pharmacologically 
diverse compounds, 
cognition enhancing 
drugs were shown to cluster very tightly with one another relative to other 
compounds (see figure 1) (8).   
In addition to multi-electrode EEGs, there are number of other useful tools 
available. Transgenic mouse models are highly useful for the discovery and 
development of therapeutic drugs (9). In fact, phenotypic drug discovery, such 
as the use of transgenic mouse models of disease, was responsible for 
development of 56% of first in class molecules (molecules with novel 
mechanisms of action) between 1999 and 2008 (10).  
The combination of EEG and transgenic mouse models provides a powerful tool 
for assessing the therapeutic potential of drugs for brain disorders. For 
example, Levetiracetam, a drug traditionally used to treat epilepsy sufferers, 
Figure 1: Hierarchical clustering of compounds using EEG 
parameters taken from rats instrumented with epidural 
electrodes in different cortical areas (5). 
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has been shown to have additional therapeutic potential after partially restoring 
cognitive deficits in a mouse model of Alzheimer’s disease (11).  
Due to the success of mammalian research in elucidating the mechanisms of 
action of compounds and relative lack of viable alternatives, the number of 
animals used in pharmaceutical research, is extremely high. Over two hundred 
thousand mammals were used, for a variety of purposes, in pharmaceutical 
research and development in 2013, eight and a half thousand of which were 
used for surveying drug pharmacodynamics and pharmacokinetics (12).  
However, although the use of mammals in pharmacological research is very 
popular, there is a high financial cost. This is partially due to the high standards 
of care and regulatory requirements for housing and working with animals. 
Animal units must be temperature controlled, have air filtered ventilation, and be 
highly secure among a host of other specific requirements. In addition, mice 
take between forty and sixty days to reach sexual maturity with a gestation 
period of a further three weeks (13). These limitations make breeding mice for 
animal experiments a relatively time consuming and expensive process.  
Moreover, in the case of EEG brain recordings, the experiments themselves are 
highly invasive and stressful procedures. Even epicranial EEG insertion 
requires surgery under general anaesthetic and runs the risk of infection. 
Moreover, due to tissue injury, related to the invasiveness of electrode 
implantation, inflammation is likely to occur (14). Inflammation is problematic 
because it has been implicated in epileptogenesis, thus furthering the suffering 
experienced by the animal while making them unsuitable for research (15). In 
addition, multi-electrode EEG recordings have relatively poor spatial resolution 
as the number of possible electrodes is limited. 
All of these factors suggest there is a strong need for alternative models for 
assessing CNS effects of drugs. One such alterative gaining traction is the 
zebrafish (16).  
 
Zebrafish EEG models for screening pharmacological compounds and the utility 
of zebrafish as tools for assessing neuropharmacological agents. 
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The zebrafish has a number of advantages that make it an attractive animal 
model. Zebrafish females take around three months to mature, spawn around a 
hundred eggs at a time and spawn every few days (17). Extremely high rate of 
reproduction and the fact that zebrafish embryos are not a protected species 
until four days post fertilisation makes them an ideal candidate for high-
throughput pharmacological testing (18).   
The utility of zebrafish for observing drug effects is already well established. 
Zebrafish have been used in high throughput behaviour based screens in 
attempts to identify CNS active compounds with novel structures, targets and 
functions (2,16,19–21). However, behavioural readouts, while a useful marker 
of brain activity, often diminish complex and varied brain function into basic 
metrics that do not fully represent the underlying brain mechanisms. Direct 
recordings of brain activity patterns have been utilised in order to better assess 
drug activity and side effects. Local field potential recordings have high 
temporal resolution and provide a good summation of fast brain electrical 
activity but only of a relatively small area of brain tissue (22). The relative ease 
with which genetic modification can be undertaken on zebrafish means they are 
ideal organisms on which to perform phenotype based screening. One such 
study, utilised a snc1lab mutation, to produce a transgenic zebrafish with photo-
sensitive seizure-genesis. Using a seizure modelling algorithm, the ability of a 
wide variety of compounds to prevent or reduce seizure perpetuation could be 
realised. A measure of local field potential (LFP) complexity was found to 
negatively correlate with the presence of the snc1lab mutation. Interestingly the 
drug clemizole did not improve LFP complexity scores and was therefore not 
considered significantly efficacious in the LFP screening, despite being shown 
to reduce the number of spontaneous seizures (23). Conversely, clemizole has 
been identified as efficacious in a number of different screens using similar 
model organisms but with different approaches in terms of analysis and 
methodology (24). It is possible these discrepancies in results, with regard to 
clemizole, occur as a result of the poor coverage allowed of local field potential 
recordings; seizures may not be properly identified due to recordings only being 
taken from a very specific area.  
Furthermore, zebrafish have been used in combination with multi-channel EEG 
recordings to study Pentylenetetrazole (PTZ) induced seizures. It was found 
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that seizures were largely propagated through the telencephalon. However as 
the electrode array only recorded from the midbrain and telencephalon, 
propagation through other regions cannot be excluded (25). This highlights the 
limitations of electrophysiological experiments, as even multi-electrode arrays 
have relatively poor coverage of all brain areas. 
A similar study demonstrated the viability of machine learning approaches for 
automatic detection of seizures in zebrafish (26). The study in question utilised 
multiple models of seizures including pharmacologically induced seizures via 
PTZ and seizures in genetically modified models. Local field potential 
recordings and inducible seizures in combination with automated seizure 
detection could provide a powerful screening model of anti-epileptic drugs (26). 
Moreover, hyperthermia induced seizures have been shown to be dependent on 
TRPV4 channels as demonstrated by utilising TRPV4 antagonist RN-1734. In 
further analyses it was shown that seizures could also be attenuated by 
exposing fish to post-synaptic glutamate antagonists, thus supporting the theory 
that hypothermia induced seizures are partly mediated by NMDA receptor 
dependent glutamate transmission (27).  
It’s clear that EEGs can be used in conjunction with zebrafish to great effect and 
have already demonstrated their power in pharmacological research, 
particularly, in the field of epilepsy. However, there are limitations with regard to 
EEGs. In particular, EEGs and LFPs merely provide a summation of brain 
activity and even with the use of multi electrode arrays it is difficult to localise 
brain activity to specific areas. Being able to identify multiple specific areas of 
activity would allow for a better understanding of network connectivity and 
whole brain dynamics. In contrast with EEG, brain imaging techniques have 
been shown to be well adapted for these purposes and zebrafish, with their 
transparent epidermis, are perfectly suited for use in conjunction with imaging 
techniques (28). 
 
Calcium imaging of neuronal activity. 
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The ability to record activity from multiple brain regions simultaneously and 
specifically is imperative in order to better understand the functioning of 
neuronal networks. Calcium imaging is one approach that can be used for 
imaging large populations of neurons and is a useful tool for assessing 
functional networks (29). Calcium transients are excellent markers of neuronal 
activity due to the strong relationship between intracellular Ca2+ ions in the 
presynaptic terminal and neurotransmitter release (see figure 2). The extent of 
action potentials controls the amount of Ca2+ that enters the presynaptic 
terminal which in turn effects the amount of neurotransmitter released. 
Moreover, action potentials usually produce a very brief rise in Ca2+ ions. This is 
due to a combination of Ca2+ channels being open a very short amount of time 
and Ca2+ ions being 
rapidly buffered by 
calcium binding proteins 
(30). These properties 
make Ca2+ an ideal 
marker of neural activity 
because it can represent 
neurotransmitter release 
at high spatial resolution. 
Due to the effectiveness 
of using Ca2+ ions as a 
measure of brain activity a 
number of genetically 
encoded calcium indicators have been developed; prominent among which is 
the GCaMP family of sensors. GCaMPs have been a popular approach for 
measuring calcium activity and have been continually updated and improved 
over the course of the last two decades (31–33). One of the more recent 
members of this family, GCaMP6, has been shown to reliably detect single 
action potentials in the mouse visual cortex when comparing fluorescent activity 
to simultaneous in vivo electrophysiology.  Indeed, it was evident that GCaMP6 
detected three-fold more neuronal responses than its predecessor, GCaMP5G, 
and could even detect calcium transients in dendritic spines. Moreover, 
Figure 2: The relationship between intracellular Ca2+ and 
neurotransmitter release rate (27). 
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because GCaMPs are genetically encoded, it is possible to express them in 
specific cell subpopulations (34).  
In zebrafish, GCaMPs can be genetically encoded under the pan-neuronal 
elavl3 promotor, 
allowing constitutive 
expression 
throughout the brain. 
Larval zebrafish 
provide an ideal 
framework for 
calcium imaging of 
this type due to the 
relative ease with 
which genetic 
modification can be 
done and their largely 
transparent epidermis (16).  
The combination of advanced microscopy techniques, GCAMP calcium sensors 
and larval zebrafish provides a powerful approach for brain network analysis 
due to the exceptionally high spatial resolution available. Xudong Lin at al 
utilised GCaMP sensors to record brain wide activity in zebrafish larva at single 
cell resolution using confocal microscopy. Zebrafish were exposed to a variety 
of different neurotoxins and their brain wide activity was recorded. This 
experimental technique allowed for the detection of the distinct spatio-temporal 
patterns of activation induced by different neurotoxins, as illustrated in figure 3 
(35). 
A similar experiment setup, combining transgenic GCaMP6s zebrafish and 
wide-field fluorescence microscopy has been used for mapping of neuronal 
activity during pentyltetrazole (PTZ) induced seizures. This study demonstrated 
the concentration-dependent effect of PTZ on zebrafish brain dynamics in terms 
of signal amplitude and frequency. Moreover, a PTZ concentration-dependent 
increase in functional connectivity was also shown to be present (36). The use 
of a wide-field fluorescent microscope, in this study, meant that image data will 
only be of super-imposed fluorescent activity across the zebrafish brain. This is 
Figure 3: Neural activity density map of a representative 
elavl3:GCaMP5 zebrafish larva under treatment of different 
neurotoxin peptides (33). 
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because wide field fluorescent microscopes can only image in 3-dimensions (2 
spatial dimensions over time). As such, region of interest selection can only be 
of the most rudimentary nature and thus cannot provide a comprehensive 
perspective whole brain activity.  
Alternative approaches to widefield fluorescence microscopy include imaging 
techniques such as two photon (37), confocal (38) and light-sheet microscopy 
(LSM) (39). However, while these techniques allow three-dimensional imaging 
of tissue at very high spatial resolution, temporal resolution is sacrificed relative 
to widefield fluorescence microscopy. Two photon and confocal microscopy are 
particularly slow when performing volumetric imaging because both techniques 
are based on scanning and therefore only image a small area at a time. In 
addition, confocal microscopy is limited to a depth of around 50µm and two 
photon microscopy, due to its use of longer wave length light, comes with the 
risk of localised heating and the resultant damage (39). As such neither 
approach is ideal for imaging the whole zebrafish brain. Conversely LSM 
illuminates a single optical plane at a time, collecting fluorescence from all 
excited molecules within the field of view. LSM, therefore, can image 10 optical 
sections, enough to encompass an entire zebrafish larvae, within 1.9 seconds 
(4). Light sheet microscopy, therefore, provides respectable temporal resolution, 
while still offering excellent volumetric coverage. It is for this reason that it is the 
imaging approach of choice for this study. 
 
Analytical approaches to 4-dimensional brain activity data and how it has been 
used in the past to model brain function. 
 
The combination of LSM, GCaMP calcium sensors and zebrafish allows for 
imaging of four-dimensional brain activity (three spatial dimensions over time). 
Imaging over time, which is known as functional imaging, generates large data 
sets. Consequently, it is often necessary to condense some of this data, either 
to make it more understandable or less computationally intensive. A common 
way of doing this is by combining individual voxels from the 3d images into 
regions of interest (ROIs). 
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ROIs can be assigned to regions based on established cytoarchitecture or 
some other defined anatomical architecture. Atlases for cytoarchitecture exist 
for a number of species including the mouse (40) and macaque (41). Brain 
atlases have also been developed for use in zebrafish. One such atlas uses a 
variety of techniques to identify regions related to specific behaviours and 
stimuli in larval zebrafish between 5 and 7 days post fertilisation (DPF) (42).  
Mapping ROIs to an atlas is advantageous as it allows inferences to be made 
about why specific regions behave in a certain way as ROIs are delineated 
based, to a certain degree, on the current understanding of their functional 
capacity.  However, this approach is not without issues: for example it does not 
account for significant amounts of variability between individuals but rather 
assumes a certain degree of uniformity. This downside could be particularly 
relevant in the case of larval zebrafish because small differences in the number 
of DPF could have significant effects on brain anatomical architecture (43).  
Moreover, it is possible that larger anatomical regions could contain functionally 
discrete populations of neurons, meaning the true properties of the network are 
distorted due to mixing distinct signals of activity (44).  
A viable alternative to defining ROIs according to predefined anatomical areas, 
is to randomly aggregate voxels into ROIs of equal size (45). This approach 
allows for a certain degree of choice in terms of node size and number. In the 
case of zebrafish this is useful because, with such high spatial resolution, the 
size of selected ROIs can be chosen based on the smallest possible 
functionally distinct region. In this case it is often necessary to repeat analyses 
with a different random parcellation for each, in order to ensure consistent 
findings.   
In addition to random parcellation ROIs can be selected in a data driven manner 
using clustering algorithms. One such algorithm combined clustering of voxels 
based on their functional similarity with a spatial constraint function. This 
allowed the creation of similar sized ROIs, each containing functionally similar 
voxels. However, it has been demonstrated that while this approach was an 
improvement over selecting ROIs using an anatomical atlas it was not a 
significant improvement over random parcellation approaches (46).  
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Once ROIs have been selected there are plethora of analytical approaches that 
can be utilised to make sense of the generated data, the starting point for a 
number of analytical approaches is calculating the functional connectivity. 
Functional connectivity is an approach whereby the correlation co-efficient or 
another method of time dependent similarity is calculated between all pairs of 
ROIs in a brain network. This quantifies the level of similarity over time between 
all the different brain regions. How brain regions relate to one another is directly 
related to brain function. Functional connectivity has been used to identify 
differences in resting state fMRI between healthy controls and people with 
internet addiction tendency (47), schizophrenia (48) and borderline personality 
disorder (49) as well as being used a predictor of treatment response to 
antipsychotic medication (50).  
Functional connectivity is therefore a very well-studied marker of brain function. 
How functional connectivity is optimally compared between experimental groups 
is dependent on the amount of available data, number of experimental groups 
and aims of individual researchers. A commonly used approach is network 
based statistics (NBS). NBS utilises permutation testing to statistically test the 
overall differences in the functional connectivity networks of two different 
groups. NBS is a useful tool as it provides a statistical significance cut-off for 
comparisons of experimental groups, however it cannot be used to make 
statistical inference about specific region-region functional connectivity values 
(49). Moreover, it is not useful for comparing large numbers of experimental 
groups to one another as it is both computationally intensive and would need to 
be corrected for multiple comparisons. 
Instead of attempting to make elucidations about whole networks, many 
experimenters prefer to focus on specific region to region changes in functional 
connectivity. For example, linear regression analyses have been used to 
identify relationships between functional connectivity in specific cortical areas 
and the progression of Parkinson’s disease (51). Making inferences about 
functional connectivity between specific brain regions is easier to put into the 
context of wider literature and opens up discussion about specific neuro-
anatomical mechanisms that may be driving findings.  
Functional connectivity analyses, however, do not provide a full picture of brain 
activity. Functional connectivity is an analysis method focused largely on 
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assessing the similarity between regions of interest and overlooks information 
pertaining to variability in localised temporal brain dynamics. Temporal 
information is manifest in individual time series. One such study, utilising 
GCaMP6s zebrafish used characteristics of temporal dynamics, in the form of 
parameters such as peak amplitude and frequency, to assess the effect of PTZ 
on brain activity (36). While in this particular case the imaging data were 3-
dimensional (two spatial dimensions and time) this approach easily translates to 
4-dimensions. Simple peak-based measures provide variables relating to 
temporal dynamics that are not measured explicitly in functional connectivity 
analyses. Peak parameters extracted from 4-dimensional brain activity data  
have already been utilised in the context of convulsant-treated larval zebrafish 
to highlight differences in temporal dynamics between pharmacologically 
distinct pro-convulsant compounds (4).  Similar approaches have been used in 
the study described here, however, in this context they are paired with 
multivariate clustering approaches similar to those utilised during clustering of 
spectral indices extracted from EEG data in mice (8).  
 
The overall aim of this thesis was to highlight the utility of 4-dimensional 
functional imaging of elavl3:GCaMP6s zebrafish for the assessment of drug 
function and the identification of unwanted side effects. 
Objectives 
To address the overall aim, this thesis addressed the following main objectives: 
1. The first objective was to identify if compounds with specific 
pharmacologies or potentially seizurogenic properties induce common 
spatio-temporal patterns of activation in the zebrafish brain (chapter 2). 
This was achieved by exposing zebrafish, with genetically encoded 
calcium sensors, to a variety of compounds with varying pharmacologies 
and seizurogenic profiles. Four-dimensional activity data were extracted, 
from which parameters were calculated that reflected the spatio-temporal 
patterns of activation induced by the different compounds. Clustering was 
then performed on these parameters to identify if similar compounds with 
similar pharmacological or seizurogenic profiles cluster together based on 
these parameters. 
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2. Moreover, I wished to identify whether classification algorithms were able 
to discriminate between drugs, with and without seizurogenic properties, 
based on their spatio-temporal dynamics in the zebrafish brain (chapter 
3). A variety of classification learning algorithms were generated and 
tested using the same parameters used for the clustering analyses. 
 
3. In addition, I sought to train and test classifiers using hold out data (data 
not used during the generation of the algorithm), in order to obtain 
information about generalisability (chapter 3).  
 
Chapter Two: Data acquisition and Clustering 
Introduction 
All analyses in this thesis were performed using 4-dimensional brain activity 
imaged from zebrafish larvae. As described in chapter one zebrafish larvae 
have a plethora of advantages over their mammalian counterparts, not least, 
being a more ethical and cost effective alternative. Also highlighted was the 
utility of a combination of light-sheet microscopy, GCaMP calcium sensors and 
transgenic zebrafish for providing a real-time model of whole brain activity. The 
work described in this thesis uses such an experimental model for the 
generation of 4-dimensional brain activity data. 
This chapter of the thesis will discuss the methods used to generate the 4-
dimensional brain activity data in addition to a number of analyses performed. 
These analyses are concerned with identifying whether compounds with 
specific pharmacological mechanisms or seizurogenic profiles induce specific 
patterns of activity in the brain. This question is of the utmost importance with 
regards to demonstrating the utility of zebrafish, as a viable alternative to 
mammals, in the area of drug safety screening and pharmacological profiling.  
The ability to effectively determine if drugs are potentially seizurogenic is 
paramount to assessing the safety of neurotropic drugs (52). This can be a 
complex task, because drugs have varying degrees of seizurogenicity and there 
is a large variety of mechanism through which compounds can elicit a 
seizurogenic effect (53–55). As such, approaches used to assess such 
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compounds must be able to consider a spectra of drug effects. The main 
advantage of the experimental approach used in this thesis is the ability to 
record activity from the whole brain, meaning activity indicative of 
seizurogenesis occurring in specific brain regions will likely be detected. If 
known seizurogenic compounds elucidate a similar and specific pattern of 
activation in the zebrafish brain it validates this experimental setup as an 
effective screening approach.  
In addition to identifying potentially seizurogenic compounds, I wished to see if 
there were patterns of activation indicative of specific pharmacologies. Being 
able to make inferences about the pharmacology of compounds based on 
zebrafish brain activity data would provide information about the applications of 
compounds before clinical trials are conducted. Moreover, it has the potential to 
provide insight into new applications of compounds currently used for different 
therapeutic purposes. Ketamine for example has come to the forefront in recent 
years as a highly effective antidepressant, despite not traditionally being used 
for such purposes (56). In addition, it is imperative that novel ways of assessing 
neurotropic drugs are developed, as current approaches have failed to produce 
effective therapies for large proportions of both epilepsy sufferers (57) and 
people with depression (58).  
In this thesis, a number of parameters were measured that quantify the spatio-
temporal properties of the 4-dimensional zebrafish brain activity. These 
parameters were analysed using univariate and multivariate approaches in 
order to assess whether common spatio-temporal patterns of activation exist 
between drugs with similar seizurogenic or pharmacological properties.  
Methods 
Methods Section 1: Data acquisition  
The experimental approach and data acquisition, including the extraction of 
timeseries from the 4-dimensional image data and the extraction of the peak 
parameters was performed as previously (4). Below is a brief outline of the 
process, more detail is available in the original paper (See (4) appendix A).  
Model organism 
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Transgenic elavl3:GCaMP6s zebrafish with an unpigmented epidermis. Fish 
were used four days post fertilisation (4dpf). These fish express GCaMP6s in the 
cytoplasm under control of the pan-neuronal elavl3 promotor meaning that the 
Ca2+ sensor is expressed in virtually every neuron of the CNS (59). This model 
allows us to visualise neural activity, as changes in fluorescence intensity, across 
the whole CNS in response to treatment with neuroactive drugs.   
 
Figure 4: Confocal maximum intensity projection image of a 4dpf elavl3:GCaMP6s larva (10x 
magnification). Scale bar: 100µM. 
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Test Compounds 
Forty-three compounds were selected for study which included multiple 
representatives of GABAA receptor antagonists, antidepressants, muscarinic 
agonists, acetylcholine esterase inhibitors, δ-opioid agonists and glutamate 
subtype agonists (details on drug names, uptakes and specific mechanisms of 
action are included in table 1). Appropriate exposure times and exposure 
concentrations were determined based on previous data, literature information 
and pilot work. 
In addition, information on the bioavailability of the compounds tested 
(percentage uptake into the body) were based on previously conducted studies 
with zebrafish embryo-larvae (publication in progress). 
Compound Exposure and LSM 
Drug exposure and LSM was performed as described previously in (4). Briefly, 
larvae were exposed to each drug in a single well of a twenty-four well plate. 
Following exposure, larvae were subsequently exposed to the neuromuscular 
blocker tubocurarine (4mM) until cessation of movement. Each drug was tested 
at three concentrations (outlined in Table 1) alongside an unexposed control 
group. Eight larvae were used per concentration, although in some cases this 
number varied due to loss of animals, failure of data sets to correctly process 
experimental error with regard to the registration of ROIs to the 4-dimensional 
image data. As ROIs are based on an anatomical atlas and there is a degree of 
heterogeneity between larvae there is, consequently, a degree of ROI registration 
error. In addition, eight control experiments were run alongside each compound 
whereby fish were exposed to embryo culture water only. After exposure to the 
test compound, fish were transferred into 1.4% low melting point agarose 
containing the test compound and tubocurarine. Optical sectioning was executed 
in the horizontal plane from the dorsal to the ventral surface of each larva. Optical 
sectioning was repeated for six minutes generating two hundred cycles, each 
comprising ten z-stacks. Each z-stack took approximately 1.875 seconds to 
capture. 
 
Image processing and analysis 
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Image processing was performed using a custom python image processing 
pipeline as previously described (4). Briefly, a labelled reference brain was 
aligned to each image and fifty regions of interest (ROIs) were selected in order 
to provide representatives of all the major brain regions (see table 2) (60). The 
mean fluorescent intensity across all the voxels within each ROI was calculated 
generating a time series of neural activity for each ROI (see figure 4). Peak 
analysis was then performed on each timeseries, producing nine peak 
parameters for each ROI within each animal:  mean peak height, peak width, 
peak separation in frames, area under the curve and number of peaks. For this 
all the time series were filtered using Gaussian filtering (sigma = 1.5) to remove 
high frequency noise. The baseline of the smoothed signal was subtracted and a 
threshold of two times the standard deviation was used to identify peaks.  
 
Figure 5: Example timeseries from larvae exposed to four pharmacologically distinct drugs. Graphs depict 
mean fluorescent intensity for each ROI (represented by distinct lines) on the y-axis and time in number of 
frames on the x-axis. Note the coordinated activity response profiles across multiple ROIs for each drug. 
Each graph is a single representative experiment. All the timeseries have their linear trend removed in order 
to provide a better perspective of the peak heights. 
 
Page | 21 
 
 
 
  
    Exposure conditions % uptake 
across 
range 
Compound CAS No. Mode of Action Concentrations   Duration 
Donepezil 884740-09-4 ACh esterase inhibitor (61) 125, 62.5, 31.25μM 30mins 349.65 
Physostigmine  57-64-7 ACh esterase inhibitor (62) 500, 250, 125μM 20mins 43.21 
Tacrine 1684-40-8 ACh esterase inhibitor (61) 1, 0.5, 0.25mM  20mins 16.44 
Clozapine 5786-21-0 Atypical antipsych (polypharm) (63) 100, 50, 25μM 20mins 958.70 
Olanzapine 132539-06-1 Atypical antipsych (polypharm) (64) 250, 125, 62.5μM 20mins 88.43 
Bicuculline 40709-69-1 GABAA antagonist (65) 250, 125, 62.5μM 30mins 1.00 
Pentetrazol (PTZ) 54-95-5 GABAA antagonist (66) 5, 2.5, 1.25mM 20mins 8.00 
Picrotoxin 124-87-8 GABAA antagonist (67) 60, 30, 15μM 20mins 2.00 
Bemegride 64-65-3 GABAA antagonist (68) 1, 0.5, 0.25mM  20mins N/A 
Gabazine 104104-50-9 GABAA antagonist (69) 1, 0.5, 0.25mM  20mins 1.03 
Kainic acid 58002-62-3  Glutamate subtype agonist (Kainate) (70) 1, 0.5, 0.25mM  30mins <LOQ 
Cis-ACPD 477331-06-9 Glutamate subtype agonist (NMDA) (71) 2, 1, 0.5mM  30mins N/A 
NMDA 6384-92-5 Glutamate subtype agonist (NMDA) (72) 2, 1, 0.5mM  30mins N/A 
Strychnine 60-41-3 Glycine antagonist (73) 200, 100, 50μM 20mins 36.00 
4-aminopyridine 504-24-5 Non-selective K+ blocker (74,75) 1, 0.5, 0.25mM  10mins 9.00 
Tetraethylammonium 
Cl 
 56-34-8   Non-selective K+ blocker (76) 1, 0.5, 0.25mM  1 hour N/A 
Bupropion 31677-93-7 Mixed mechanism antidepressant (77) 60, 30, 15μM 30mins 63.00 
Maprotiline 10347-81-6 Mixed mechanism antidepressant (78) 31.25, 15.6, 7.8μM 20mins 9.00 
Amoxapine 14028-44-5 Mixed mechanism antidepressant (79) 62.5, 31.25, 15.6μM 20mins 34.00 
Amitriptyline 549-18-8 Mixed mechanism antidepressant (80) 125, 62.5, 31.25μM 20mins 863.78 
Pilocarpine 54-71-7 Muscarinic agonist (81) 10, 5, 2.5mM 30mins 7.64 
Muscarine  2936-25-6 Muscarinic agonist (82) 1, 0.5, 0.25mM  1 hour 0.93 
Bethanechol 590-63-6 Muscarinic agonist (83) 1, 0.5, 0.25mM  1 hour 0.50 
Aminophylline 317-34-0 Phosphodiesterase and Adenosine (84) 2, 1, 0.5mM 30mins 2.00 
Theophylline 58-55-9 Phosphodiesterase and Adenosine (85,86) 1, 0.5, 0.25mM  20mins N/A 
Caffeine 58-08-2 Phosphodiesterase and Adenosine (87) 1, 0.5, 0.25mM  20mins 19.65 
SNC80 156727-74-1 δ-opioid agonist (88) 100, 50, 25μM 20mins 224.67 
SB205607 
dihydrobromide  
1217628-73-
3  
δ-opioid agonist (89) 500, 250, 125μM 20mins 24.33 
Cocaine 53-21-4 Dopamine transporter inhibitor (90) 250, 125, 62.5μM 20mins 150.55 
Amphetamine 51-63-8  Dopamine, 5-HT and noradrenaline (91) 1, 0.5, 0.25mM  20mins 76.14 
            
4-Aminophenylsulfone 80-08-0 Antibiotic (sulphonamide-like) (92) 1, 0.5, 0.25mM  20mins 7.78 
Clonidine 4205-91-8 a2 agonist (in CNS) (93) 1, 0.5, 0.25mM  20mins 25.50 
Quinine HCl 6119-47-7 Alkaloid antimalarial (94) 1, 0.5, 0.25mM  20mins 11.28 
Yohimbine 65-19-0 Alkaloid a2 antagonist (95) 1, 0.5, 0.25mM  20mins 49.17 
Mizolastine 108612-45-9 H1 antihistamine (96) 100, 50, 25μM 20mins 185.60 
Emetine 316-42-7 Alkaloid (97) 500, 250, 125μM 1hour 33.77 
Apomorphine 41372-20-7 Dopamine agonist, 5HT and a2 antagonist (95) 100, 75, 50, 25μM 1hour 77.77 
Cisplatin 15663-27-1 DNA cross linking chemotherapeutic (98) 500, 250, 125μM 2hours 3.00 
Morphine 52-26-6  μ-opioid receptor activator (99) 1, 0.5, 0.25mM  2hours 2.60 
Rolipram 61413-54-5 Phosphodiesterase-4 inhibitor (100) 300, 150, 75μM 24hours 24.39 
Ketamine  1867-66-9 Glutamate subtype antagonist (NMDA) (101) 62.5, 31.25, 15.6μM 20mins 214.23 
Nomifensine  32795-47-4 Noradrenalin and dopamine uptake inhibitor 
(102,103) 
100, 50, 25μM 20mins 255.51 
Ketoconazole 65277-42-1 CYP17c inhibitor (104) 100, 50, 25μM 20mins 567.05 
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Methods Section 2: Data analysis 
Overview of hierarchical clustering 
Hierarchical clustering was performed using parameters that quantified the effect 
of each compound on spatio-temporal dynamics. I extracted two distinct but 
complementary sets of parameters from the mean fluorescent intensity data that 
are indicative of the spatio-temporal patterns of activity. One set was derived from 
analysis of peaks of time series in each region of interest, and the other was 
derived from functional connectivity analysis. Subsequent analysis, including 
hierarchical clustering, was performed separately on each set of parameters. For 
each set of parameters, I formed a vector representation of each compound and 
the euclidean distances between each of the vectors was calculated and used for 
hierarchical clustering (105–108). The hierarchical clustering, for each of the two 
sets of parameters, produced a dendrogram, which represents each of the 
compounds similarity to one another in terms of either their peak parameters or 
functional connectivity.  
Data used in subsequent advanced statistical analysis (input data) 
The experimental unit was considered to be the data obtained, as described in 
‘methods section one’, from one individual larva imaged for approximately 200 
time-cycles, each cycle comprising 1 z-stack of 10 z-slices (to be referred to 
herein as a “frame”). Experiments below one hundred and ninety-eight frames in 
length were removed from analyses. This was done in order to ensure all 
timeseries were equally representative and to make sure parameters were not 
biased by the length of experiment.   
As previously stated, the image processing pipeline generated mean fluorescent 
intensity data for 50 ROIs comprising all major brain regions. It was imperative 
that all experiments used for analyses contained the same number of ROIs, this 
Table 1 (previous page): All compounds used in the current study. Colour coding in the left most column 
represents the seizure generating propensity of the compounds in question. Green represents compounds 
with no known seizure genic properties and red represent compounds with known associations with 
seizure. Column 3 shows the pharmacological class to which each compound belongs. Columns 4 and 5 
show the exposure conditions used for the ‘in life’ component of the experiments, and column 6 the % 
uptake exhibited by each compound based on the whole-body burden versus the external exposure 
concentration as determined by the previously undertaken chemical analysis of compound uptake.  
 
 
 
 
 
 
 
used for the ‘in-life’ component of the experiments  
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was necessary in order to ensure consistency. As a result eight ROIs were 
excluded from all analyses. ROIs included and excluded are outlined in table 2. 
ROIs were excluded if they were missing more than fifteen times across all 
experiments for all compounds. Such ROIs were considered to be frequently 
missing. ROIs were marked as missing if the mean intensity signal was zero 
across all the frames recorded in a single experiment. The reason for the absence 
of such frames was a failure of the image processing pipeline to correctly register 
that region, typically as the region consistently lay at the extreme of the imaging 
range (i.e. at the very top or bottom of the image z-stack such as the pituitary).  
After removing all ROIs deemed to be missing frequently, individual experiments 
were removed from analyses if they had non-frequently missing ROIs. That is to 
say, experiments were removed from analyses if they contained a ROI that was 
missing in less than 14 other experiments. 
As stated above ROIs were excluded if missing more than fifteen times. The 
number fifteen was chosen in order to strike a balance between the number of 
ROIs excluded from analyses and the number of experiments excluded from 
analyses. This is because if a large number of ROIs are excluded then coverage 
of the zebrafish brain is lost and if a large number of experiments are lost n-
numbers for compounds go down.  
There were forty-four different compounds including the control group. The 
number of experiments for each compound, not including control, varied between 
six and twenty-seven, with a mean of twenty-two.  
The total number of control experiments was three hundred and thirty-three. The 
large amount of variation in number of experiments per compound was due to 
some compounds having poor registration for ROIs that were not frequently 
missing across all experiments. This meant a large number of experiments from 
these compounds had to be excluded from analyses.  
In addition to the mean intensity data and peak analysis parameters provided by 
the image processing pipeline, for each experiment a functional connectivity 
matrix (109) was generated by calculating the Pearson correlation coefficient 
between the time series of all possible pairs of ROIs. Several alternative 
measures were considered, including cross correlation and coherence, the merits 
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and disadvantages of which are discussed in later chapters. Pearson correlation 
coefficient was chosen because it is simple to understand and implement while 
considering the amplitude and phase of any underlying oscillatory activity.  
Connectivity matrices are designed to give an indication of the level of functional 
similarity present between different ROIs and thus provide information on how 
functionally connected each ROI is to every other ROI. A schematic providing an 
overview of initial data input generation process is provided in Figure 5. 
The correlation coefficient between two time series was calculated as (eqn 1)  
𝑟𝑥,𝑦 =  
∑ (𝑥𝑖 − ?̅?)(𝑦𝑖 − ?̅?)
𝑛
𝑖=1
√∑(𝑥𝑖 − ?̅?)2 ∑(𝑦𝑖 − ?̅?)2
, (𝑒𝑞𝑛 1) 
Here, 𝑛 is the number of time points in each time series, 𝑥 and 𝑦 the time series 
vectors of fluorescent intensity over time, 𝑥 ̅ and ?̅? are the mean of the 
corresponding timeseries and 𝑟𝑥,𝑦 is the Pearson’s correlation coefficient between 
𝑥 and 𝑦:  
To generate a functional connectivity matrix, each ROI was compared to every 
other ROI, using the correlation coefficient (eqn 1). Each row and column of the 
resulting matrix represents a different ROI and the matrix element positioned at 
the intersection of each row and column is the correlation coefficient between the 
two corresponding ROIs (see Figure 5).  
Here, 𝑋 is a 𝑚 − 𝑏𝑦 − 𝑜 matrix of time series such that 𝑚 is the number of time 
points and 𝑜 is the number of ROIs. Here, 𝑅 is a connectivity matrix of 𝑋 such that 
𝑅 is given by: 
 
𝑅 =  [
𝑟𝑥1,𝑥1 ⋯ 𝑟𝑥𝑜,𝑥1
⋮ ⋱ ⋮
𝑟𝑥1,𝑥𝑜 ⋯ 𝑟𝑥𝑖,𝑥𝑜
] , (𝑒𝑞𝑛 2) 
The connectivity matrix is symmetric along the diagonal, with all the values along 
the diagonal being equal to one. As a result of this, only the values in the upper 
triangle of the connectivity matrix 𝑅, excluding the diagonal, were selected for 
further analyses. This was done to remove repetitions of correlation coefficients 
and comparisons of ROIs to themselves. 
Page | 25 
 
 
 
 
 
 
Table 2: Colour coding represents anatomical categorisation as subdivisions of the 
diencephalon, mesencephalon, rhombencephalon and telencephalon, along with ganglia 
respectively from top to bottom. 
 
 
 
Region of interest used in analyses ROIs excluded from analyses
Diencephalon Pituitary
Dorsal thalamus Torus lateralis
Eminentia thalami
Habenulae
Pineal
Posterior tuberculum
Preoptic area
Pretectum
Ventral thalamus
Mesencephalon
Tectum stratum periventriculare Caudal Hypothalamus
Tectum neurophil Intermediate Hypothalamus
Tegmentum Rostral Hypothalamus
Torus longitudinaris
Torus semicircularis
Rhombencephalon
Area postrema
Cerebellum
Corpus cerebelli
Eminentia granularis
Inferior olive
Interpendnuclar nucleus
Lateral reticular nucleus
Lobus caudalis cerebelli
Locus coeruleus
Mauthner
Medial Vestibular nucleus
Noradrendergic neurons 
Raphe Inferior
Raphe Superior
Tangential vestibular nucleus
Valvula cerebelli
Telencephalon
Anterior commissure Postoptic commissure
Olfactory bulb Optic commissure
Pallium
Subpallium
Eyes
Olfactory epithelium
Vagal ganglia
Spinal Cord
Spinal cord neuropil region
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 C 
 B 
 D 
Figure 5:  A schematic showing the approach used for the advanced analysis applied to the experimental 
datasets A: ROIs outlined in colours over a maximum intensity projection taken from a single 4dpf larval 
zebrafish brain. B: A single ‘experiments’ time series depicting the mean fluorescent intensity of the different 
ROIs over time taken from a single experiment. C: image showing the definition of each of the peak 
parameters extracted from each time series. D: Heat map of connectivity matrix comparing forty-two ROIs. 
Each element represents a correlation coefficient with dark blue elements representing strong correlation and 
light blue representing negative correlation.  
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The selected values of the connectivity matrix were then reshaped into a vector 
𝑟, which consisted of eight hundred and sixty-one unique values henceforth 
referred to as the connectivity vector. A connectivity vector was generated for all 
the experiments (see figure 6). This was done in order to generate parameters 
reflective of how the brain dynamics of regions change in relation to one another 
in response to certain compounds. The correlations were vectorised so that 
experiments could be indexed by row upon data matrix generation, as 
subsequently described. 
Next a data matrix was generated in which each row is a connectivity vector from 
a single experiment. This data matrix 𝐷 is an 𝑚-by-𝑡 matrix where 𝑚 is equal to 
the total number of experiments across all conditions and 𝑡 is equal to the number 
of connectivity parameters. Data were organised as such, so that principal 
component analysis could be performed across all experiments and over all the 
parameters. 
Figure 6: Bar graphs depicting the functional connectivity vectors of the time series in figure 4. The x-axis is each 
element of the functional connectivity vector and the y-axis is the Pearsons correlation coefficient value (measure of 
functional connectivity) for that element. Each element of the connectivity vector represents a comparison between 
two different ROIs 
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In addition, and separately to the connectivity analyses, several peak parameters 
were calculated for each of the ROIs and for each experiment. These parameters 
consisted of the peak height, peak width, peak separation, number of peaks and 
the area under the curve. These were calculated as described previously (4). The 
mean and standard deviations of each peak parameter were calculated for each 
ROI for the time span of the experiment. There were therefore nine peak 
parameters, including peak number, calculated for forty-two ROIs totalling three 
hundred and seventy-eight different values for each experiment. A data matrix 
was generated and organised in the same way as for the connectivity analyses. 
Thus, a second 𝑚 − 𝑏𝑦 − 𝑝 data matrix 𝐷 was generated where 𝑚 was equal to 
the number of experiments and 𝑝 was equal to the number of peak parameters 
for each experiment (p=333). 
Next, each of the three hundred and thirty-three peak parameters were 
normalised such that the maximum for each parameter across all experiments 
was equal to 1, and the minimum equal to -1. If * and / represent pairwise 
multiplication and pairwise division of matrices respectively then the normalised 
peak parameters are calculated using equation 3, where 𝐷𝑖,𝑚𝑎𝑥 denotes the 
largest value in the 𝑖𝑡ℎ column of data matrix 𝐷, 𝐷𝑖,𝑚𝑖𝑛  denotes the smallest value 
in the 𝑖𝑡ℎ column of data matrix 𝐷 and 𝐷𝑖 denotes all the elements of the 
𝑖𝑡ℎ columns of data matrix  𝐷:  
(𝐷𝑖 −  𝐷𝑖,𝑚𝑖𝑛 ) ∗ (
2
𝐷𝑖,𝑚𝑎𝑥 −  𝐷𝑖,𝑚𝑖𝑛 
) , (𝑒𝑞𝑛 3) 
 
Principal Component Analysis 
The data matrices of the peak parameters and connectivity parameters were 
analysed separately but identically, thus in all future descriptions analyses were 
undertaken on both sets of parameters independently of one another. Principal 
component analysis (PCA) was used to reduce the dimensionality of each of the 
two data sets while retaining the majority of the variability present across 
compounds. The principal components were computed as follows: 
First, the covariance was calculated between all possible pairs of parameters 
using equation 4, where: x is a vector of experiments of a single parameter (e.g. 
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peak number for the diencephalon) and y a vector of experiments of a different 
individual parameter (e.g. mean peak height for the diencephalon). Here, 𝑚 is 
equal to the total number of experiments. The covariance between 𝑥 and 𝑦, 𝑐𝑥,𝑦 
was calculated as 
𝑐𝑥,𝑦 =
∑ (𝑥𝑖 − ?̅?)(𝑦𝑖 − ?̅?)
𝑛
𝑖−1
𝑚 − 1
, (𝑒𝑞𝑛 4)  
Where 𝑝 is the total number of parameters. The covariance was calculated 
between all the different pairs of parameters across all experiments to produce a 
𝑝 − 𝑏𝑦 − 𝑝 covariance matrix 𝐶. Each row and column of the resulting matrix 
represented a different parameter and the matrix element positioned at the 
intersection of each row and column represented the covariance between the two 
corresponding parameters. 𝐶 was therefore a square matrix that was symmetrical 
down the diagonal such that the diagonal was the variance of each of parameter:  
𝐶   =   [
𝑐1,1 ⋯ 𝑐1,𝑝
⋮ ⋱ ⋮
𝑐𝑝,1 ⋯ 𝑐𝑝,𝑝
] , (𝑒𝑞𝑛 5) 
 
Subsequently, the 𝑛 eigenvalues and 𝑛 eigenvectors of the covariance matrix 
were calculated. Mathematically the eigenvalues and eigenvectors satisfy: 
𝐶𝑣𝑖 =  𝜆𝑖𝑣𝑖   (𝑒𝑞𝑛 6) 
The eigenvalues and corresponding eigenvectors were then sorted by 
descending size.  
The eigenvectors of the covariance matrix 𝐶 represent “directions” in the 
coordinate space in which the variability across experiments was organised. The 
amount of variability accounted for by each eigenvector decreased with the size 
of their corresponding eigenvalue. Therefore, to reduce the size of the data, but 
retain variability, the eigenvectors that contained 99% of the variability present in 
the data, were selected.  
This amount of variability accounted for by each eigenvector was directly 
proportional to the size of their corresponding eigenvalue. As such, the 
percentage of variability accounted for by each eigenvector was calculated by 
dividing the eigenvectors corresponding eigenvalue by the sum of all the 
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eigenvalues and multiplying the answer by one hundred. The number of 
eigenvectors that accounted for 99% of the variability was 127 and 211 for the 
connectivity and peak parameters respectively. 
 The original data for each set of parameters was then projected into this principal 
component space by multiplying the vector of values of each experiment by the 
eigenvectors with either the 127 or 211 largest eigenvalues (110). The data 
transformed into the principal component space is hereafter referred to as the 
principal component scores. 
 
Outlier detection 
Outlier detection was performed on all the experiments representing an individual 
compound. Outlier detection was performed by first calculating the euclidean 
distances between the vectors of principal component scores of the experiments 
for each individual compound as follows. The euclidean distance between two 
experiments for which 𝑝 and 𝑞 are their corresponding vectors of principal 
component scores, denoted as 𝑑𝑝,𝑞, is given by: 
𝑑𝑝,𝑞 =  √∑(𝑞𝑖 − 𝑝𝑖)2
𝑛
𝑖=1
   (𝑒𝑞𝑛 7) 
Here, 𝑛 is the number of principal component scores. Distances were then 
calculated between all the experiments of each compound. The resulting matrix 
of distances between all the experiments of that compound, denoted 𝐷, is given 
by: 
 
𝐷   =   [
𝑑1,1 ⋯ 𝑑1,𝑒
⋮ ⋱ ⋮
𝑑𝑒,1 ⋯ 𝑑𝑒,𝑒
] , (𝑒𝑞𝑛 8) 
 
Here 𝑒 is the number of experiments of a compound. The mean of each of the 
columns of the 𝑒 − 𝑏𝑦 − 𝑒 distance matrix 𝐷 was then calculated to find the mean 
distance each experiment was from every other experiment of the same 
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compound, hereafter referred to as the mean within compound distance. This 
was done to identify experiments that are significantly different from other 
experiments of the same compound.  
The mean within compound distances were then put into size order and the 
interquartile range (IQR) and upper quartile (UQ) were calculated. Experiments 
were excluded from further analyses if their mean within compound distance was 
more than the UQ plus one and half times the IQR of the within compound 
distances (equation 14). Thus, the experiments whose corresponding within class 
distance satisfies 𝑒𝑞𝑛 13 were removed from analyses.  
𝑑𝑖 > (𝐼𝑄𝑅 × 1.5 +  𝑈𝑄), (𝑒𝑞𝑛 9) 
 
Hierarchical Clustering 
To simplify the analysis, I sought to utilise a single representative vector for each 
compound. In order to achieve this the mean principal component scores for all 
the experiments (after exclusion of outliers) representing each compound were 
then calculated, producing a vector mean of principal component scores for each 
compound. Each element of the resulting vectors was the mean of a set of 
principal components scores across all the experiments representing a 
compound. Subsequently the euclidean distance was calculated between the 
representative vectors of all of the possible pairs of compounds. The euclidean 
distance was used to assess the level of similarity between pairs of compounds. 
These similarities can be visualised by a hierarchical clustering dendrogram. 
A hierarchical clustering algorithm was employed to cluster compounds into a 
dendrogram based on their euclidean distances. Hierarchical clustering was 
performed using a simple agglomerative method known as ‘unweighted pair 
group method with arithmetic mean’ (UPGMA) (111). UPGMA works by first 
clustering the two compounds that are the shortest distance apart. Once the first 
cluster is generated it recalculates the distances to find the average distance 
between the newly formed cluster and the remaining compounds. Let 𝑎, 𝑏 and 𝑐 
be vectors representing individual compounds and 𝑑𝑎,𝑏 represent the euclidean 
distance between 𝑎 and 𝑏. Assuming 𝑎 and 𝑏 are clustered together to form the 
cluster 𝑎𝑏, the distance between the cluster 𝑎𝑏 and the compound 𝑐 is given by: 
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𝑑𝑎,𝑐 + 𝑑𝑏,𝑐
2
, (𝑒𝑞𝑛 10) 
Once the distances between the newly formed cluster and the remaining 
compounds have been generated, the smallest distance is again selected. If that 
distance is between the newly formed cluster and another compound, that 
compound is added to the cluster. If this is not the case a new and separate 
cluster is formed between the two compounds that are the shortest distance 
apart. The algorithm repeats itself, finding the smallest distance, and connecting 
the relevant compound or cluster into a new higher order cluster. The distances 
between two clusters are calculated by simply finding the mean of the pairwise 
distances between all the compounds within each cluster.  
The UPGMA algorithm was applied to the principal components scores of each 
the compounds to group compounds together based on how similar their 
functional connectivity or peak parameters were. The UPGMA algorithm was 
chosen because all the distances between compounds contribute equally to the 
separation of each cluster.    
Mean functional connectivity 
In addition to the hierarchical clustering algorithm, the mean functional 
connectivity was calculated across all ROIs for all the connectivity values of each 
compound. This was achieved by selecting all the connectivity vectors 
representing each experiment of a compound, excluding outliers. An average 
functional connectivity vector was then calculated as the element-wise mean 
across all the experiments of a compound. Subsequently the mean of all the 
elements in the resulting vectors was calculated to generate a single mean 
connectivity ,  an approach that has been applied to evaluating the progressions 
of Parkinson’s disease (112). This was repeated for all the different compounds 
(see table 3). 
Mean peak parameters 
In addition to the hierarchical clustering algorithm, the mean of each of the peak 
parameters was calculated across all ROIs for all the input data of each 
compound. This was achieved by selecting all the peak parameters representing 
each experiment of a compound, excluding outliers. The mean peak parameters 
were then calculated by calculating the mean across all the experiments. 
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Subsequently the mean of all the peak parameters across all the ROIs was 
calculated. This was repeated for all compounds (see table 6). 
Functional connectivity between areas connected by established neurochemical 
pathways 
Established neurochemical pathways connecting ROIs were identified from the 
literature. Pathways between the relevant ROIs were listed alongside the 
neurotransmitter present in each pathway (see table 4). Subsequently, the 
elements of the connectivity matrices that represented the connectivity between 
the two ROIs connected by an identified neurochemical pathway were extracted 
from each experiment. These values were then separated into their 
corresponding compounds. 
For each compound the connectivity values representing each identified 
neurochemical pathway were compared with the corresponding connectivity 
values for water using a Kruskal and Wallis one-way analysis of variance test. 
Compounds with a significantly lower or significantly higher (p<0.05) mean 
connectivity values are included in table 4.  
Results 
Mean functional connectivity 
The mean functional connectivity across all ROIs was generated in order to 
assess if generalised functional connectivity information provides insight into 
pharmacology or seizurogenic potential. This was done in an effort to identify if 
spatial information is an important indicator of either pharmacology or 
seizurogenesis. When the mean functional connectivity scores were generated, 
and put in order of magnitude, non-seizurogenic compounds were randomly 
distributed throughout table 4 and there were no obvious similarities relating to 
their pharmacology.  
As such it seems that non-spatially specific functional connectivity information 
does not provide much insight into pharmacology or seizurogenesis. It therefore 
seems that spatially specific information is a necessary component of the 
analysis, with regards to functional connectivity.  
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With this in mind, specific functional connectivity scores between ROIs with 
known neurochemical connections, were assessed for viability as biomarkers of 
drug action.   
 
 
Functional connectivity between areas connected by established neurochemical 
pathways 
This approach identified neurochemical pathways containing specific 
neurotransmitters from the literature. Subsequently the functional connectivity 
between the two ROIs connected by the identified pathways was calculated. 
Statistical analyses was performed to identify if compounds caused increased 
functional connectivity between the two selected ROIs, relative to control.  
As an intuitive example of the reasoning behind this process, one would expect 
that the functional connectivity between ROIs connected by neurotransmitters 
Compound Mean Functional connectivity Compound Mean Functional connectivity
(≥ Control) (< Control)
Amitriptyline 0.891 Bupropion 0.744
Muscarine 0.827 Nomifensine 0.743
NMDA 0.812 Olanzapine 0.741
Bethanechol 0.805 Clozapine 0.740
Amphetamine 0.802 Morphine 0.732
Tetraethylammonium 0.799 Cocaine 0.731
Yohimbine 0.794 Bemegride 0.731
CisACPD 0.792 SB205607 0.729
Donepezil 0.792 Apomorphine 0.728
Cisplatin 0.786 Clonidine 0.725
Ketamine 0.769 Caffeine 0.720
Physostigmine 0.761 Pilocarpine 0.720
Ketoconozole 0.759 Rolipram 0.716
Kainic 0.757 Quinine 0.711
Tacrine 0.756 Aminophylline 0.711
4-Aminopyridine 0.752 Amoxipine 0.711
Emetine 0.751 Maprotiline 0.708
Water - (Control) 0.744 SNC80 0.708
Theophylline 0.697
4-Aminophenylsulfone 0.692
Strychnine 0.684
Mizolastine 0.682
Pentylenetetrazole 0.677
Picrotoxin 0.649
Bicuculine 0.646
Gabazine 0.644
Table3: Mean functional connectivity data across all ROI pairs. Left two columns contain compounds whose 
mean functional connectivity is equal to or greater than the mean functional connectivity of water. Right two 
columns are the compounds whose mean functional connectivity is less than water. 
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such as serotonin would be increased by a serotonin reuptake inhibitor. Generally 
speaking this proved not to be the case. 
 
Ref Neurotransmitter Pathways 
Drugs with increased functional 
connectivity  
Drugs with decreased functional 
connectivity 
 
(113) 
Serotonin 
Raphe Inferior - 
Telencephalon 
 Cocaine, Muscarine, Physostigmine, 
SB205607, NMDA, Amitriptyline, 
Amphetamine, Bethanechol 
Mizolastine, Picrotoxin, SNC80, 
Amoxipine, Strychnine, Bemegride, 
Clonidine, Gabazine 
 
(113) 
Serotonin 
Telencephalon - 
Pallium 
Ketamine, Ketoconazole, Muscarine, 
Physostigmine, Tacrine, Donepezil, 
NMDA, Amitriptyline, Amphetamine, 
Bethanechol, Cis-ACPD 
Morphine, Amoxipine, Strychnine, 
Gabazine, Maprotiline 
 
 
(113) 
Serotonin 
Raphe Inferior - 
Diencephalon 
 Rolipram, Amitriptyline, 
Bethanechol, SB205607, 
PTZ, Apomorphine, Amoxipine, Cocaine, 
Ketamine, Ketoconazole, Tacrine, NMDA, 
Pilocarpine, Strychnine, Aminophylline, 
Bupropion, Donepezil, 4-
Aminophenylsulfone, Bicuculine, 
Clonidine, Gabazine, Mizolastine, 
Picrotoxin, SNC80, Bemegride 
(113) Serotonin 
Raphe Superior - 
Diencephalon 
 Kainic, Rolipram, Amitriptyline, 
Muscarine, Nomifensine, 
 PTZ, Pilocarpine, Strychnine, 
Bemegride, Bicuculine, Gabazine, 
Picrotoxin, Amoxipine, 
 
(113) 
Serotonin 
Raphe Inferior - 
Preoptic Area 
 Amitriptyline, Bethanechol, 
Bicuculine, Clonidine, Gabazine, 
Picrotoxin, Quinine, SNC80, 
Theophylline, Strychnine, Aminophylline, 
Donepezil, Bemegride,  
 
(113) 
Serotonin 
Raphe Superior - 
Preoptic Area 
Bethanechol, Cocaine, Ketamine, 
Muscarine, NMDA, Cisplatin, 
Amitriptyline, Amphetamine 
 Strychnine, Bicuculine, Gabazine, 
Picrotoxin, 
 
(113) 
Serotonin 
Raphe Inferior - 
Ventral Thalamus 
 Bethanechol, Muscarine, SB205607, 
Tetraethylammonium, Apomorphine, 
Morphine, Amitriptyline, 
Amphetamine 
Gabazine, Picrotoxin, SNC80, 
Theophylline, Emetine, Rolipram, 
Aminophylline, 4-Aminophenysulfone, 
Bemegride, Bicuculine, Clonidine 
 
(113) 
Serotonin 
Raphe Superior - 
Ventral Thalamus 
 Amitriptyline, Amphetamine, 
Bethanechol, Cocaine, Muscarine, 
Tetraethylammonium, 
 Strychnine, Aminophylline, Bicuculine, 
Picrotoxin, Quinine, SNC80, 
Theophylline, 
 
(113) 
Serotonin 
Raphe Inferior - 
Posterior 
Tuberculum 
 Amitriptyline, Amphetamine, 
Bethanechol, Cis-ACPD, Muscarine, 
Tetraethylammonium 
Bicuculine, Clonidine, Gabazine, 
Picrotoxin, Quinine, SNC80, 
Theophylline, Apomorphine, PTZ, 
Pilocarpine, Strychnine, Aminophylline, 
Donepezil, 4-Aminophenylsulfone, 
Bemegride  
 
(113) 
Serotonin 
Raphe Superior - 
Posterior 
Tuberculum 
 NMDA, Kainic, Cis-ACPD, 
Muscarine 
 Amoxipine 
 
(113) 
Serotonin 
Raphe Inferior - 
Habenulae 
Clonidine, Kainic, Apomorphine, 
Rolipram, Aminophylline, Donepezil, 
NMDA 
 SB205607 
(113) Serotonin 
Raphe Superior - 
Habenulae 
 Donepezil, NMDA, Kainic, 
Amitriptyline, Nomifensine, 
 PTZ, Bicuculine, Gabazine, Picrotoxin, 
Quinine, Caffeine, Cis-ACPD, 
 
(113) 
Serotonin 
Raphe Inferior - 
Mesencephalon 
Bethanechol, Cis-ACPD, Muscarine, 
Physostigmine, SB205607, Tacrine, 
NMDA, Clozapine, Yohimbine, 
Amitriptyline, Amphetamine 
 4-Aminophenylsulfone, Gabazine, 
SNC80, Theophylline, Apomorphine, 
Rolipram, 
 
(113) 
Serotonin 
Raphe Superior - 
Mesencephalon 
 Cis-ACPD, Muscarine, 
Physostigmine, SB205607, Tacrine, 
NMDA, Amitriptyline, Amoxipine, 
Amphetamine, Bethanechol 
Theophylline, Apomorphine, Emetine, 
Morphine, Rolipram, 4-
Aminophenylsulfone, Bicuculine, 
Clonidine, Gabazine, Quinine, SNC80 
 
(113) 
Serotonin 
Raphe Inferior - 
Torus 
semicircularis 
Bethanechol, Cocaine, Muscarine, 
Tetraethylammonium, Bupropion, 
NMDA, Yohimbine, Amitriptyline, 
Amoxipine 
 Bicuculine, Picrotoxin, Rolipram, 
Caffeine, 
 
(113) 
Serotonin 
Raphe Superior - 
Torus 
semicircularis 
Bethanechol, Cocaine, Muscarine, 
Tetraethylammonium, Bupropion, 
NMDA, Yohimbine, Amitriptyline 
 Bicuculine, Picrotoxin, Caffeine, 
 
(114) 
Serotonin 
Raphe Inferior - 
Spinal Cord 
Physostigmine, SB205607, Tacrine, 
Tetraethylammonium, NMDA, 
Amitriptyline, Bethanechol, 
Muscarine 
Gabazine, Picrotoxin, SNC80, 
Theophylline, Strychnine, Bemegride, 
Bicuculine, Clonidine 
(114) Serotonin 
Raphe Superior - 
Spinal Cord 
Cis-ACPD, Cocaine, Ketamine, 
Ketoconazole, Tetraethylammonium, 
Muscarine, Nomifensine, 
Olanzapine, SB205607, Tacrine, 
Caffeine, Amitriptyline, Amoxipine, 
Amphetamine, Bethanechol, 
Physostigmine 
Clozapine, Gabazine, Kainic, 
Apomorphine, Cisplatin, Emetine, 
Morphine, Rolipram, 4AP, PTZ, 
Pilocarpine, Strychnine, Aminophylline, 
Bupropion, 4-Aminophenylsulfone, 
Bemegride, Bicuculine, Maprotiline, 
Mizolastine, Picrotoxin, Quinine, SNC80, 
Theophylline, Yohimbine, Clonidine 
(114) Serotonin 
Raphe Inferior - 
Olfactory bulb 
 Rolipram, Amitriptyline, 
Bethanechol, Muscarine, 
 Mizolastine, Picrotoxin, Quinine, SNC80, 
Theophylline, Apomorphine, Amoxipine, 
Cocaine, Nomifensine, Physostigmine, 
Tacrine, 
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 PTZ, Pilocarpine, Strychnine, 
Aminophylline, Donepezil, 4-
Aminophenylsulfone, Bemegride, 
Bicuculine, Clonidine, Clozapine, 
Gabazine, Maprotiline, 
(114) Serotonin 
Raphe Superior - 
Olfactory bulb 
 Amitriptyline, 
Cocaine, Ketamine, Ketoconazole, 
Nomifensine, Olanzapine, 
Physostigmine, Tacrine, Strychnine, 
Bupropion, 4-Aminophenylsulfone, 
Bicuculine, Mizolastine, Quinine, SNC80, 
Caffeine 
(115) Dopamine 
Diencephalon - 
Telencephalon 
 Rolipram, Amitriptyline, 
 PTZ, Pilocarpine, Strychnine, 
Aminophylline, Bicuculine, Caffeine, Cis-
ACPD, Olanzapine, Physostigmine, 
SB205607, Tacrine, 
Tetraethylammonium 
(115) Dopamine 
Diencephalon - 
Pretectum 
 Bicuculine, Clozapine, Kainic, 
Apomorphine, Cisplatin, Emetine, 
Amitriptyline, Muscarine, 
Amoxipine, Caffeine, Ketoconazole, 
Nomifensine, Olanzapine, 
Tetraethylammonium, Strychnine, 
Bemegride, Gabazine, Maprotiline, 
Quinine, Rolipram 
(115) Dopamine 
Diencephalon - 
Subpallium 
 Clozapine, Kainic, Yohimbine, 
Apomorphine, Cisplatin, Emetine, 
Rolipram, Amitriptyline, Muscarine, 
 PTZ, Strychnine, Bemegride, 
Maprotiline, Quinine, Amoxipine, 
Caffeine, Nomifensine, 
Tetraethylammonium, 
(115) Dopamine 
Ventral Thalamus - 
Subpallium 
 Amitriptyline, Amphetamine, 
Bethanechol, Caffeine, Cis-ACPD, 
Ketoconazole, Muscarine, 
SB205607, 
 PTZ, Strychnine, 4-Aminophenylsulfone, 
Clonidine, Gabazine, Kainic, Maprotiline, 
Mizolastine, Quinine, SNC80, 
Apomorphine, Cisplatin, Emetine, 
Morphine, 
(115) Dopamine 
Posterior 
Tuberculum - 
Subpallium 
 Donepezil, Cis-ACPD, Cocaine, 
Muscarine, Olanzapine, 
Physostigmine, 
Tetraethylammonium, 
 Aminophylline, Theophylline, 
Ketoconazole, 
(116) Dopamine 
Pretectum - Dorsal 
Thalamus 
 Kainic, Cisplatin, Emetine, Rolipram, 
 PTZ, Pilocarpine, Strychnine, Bupropion, 
Bicuculine, Cocaine, 
(116) 
Dopamine/ 
Serotonin 
Posterior 
Tuberculum - 
Dorsal Thalamus 
 Amitriptyline, 
NMDA, Bicuculine, Maprotiline, 
Amoxipine, Caffeine, Cis-ACPD, 
Cocaine, Olanzapine, Tacrine, 4AP, PTZ, 
Pilocarpine, Strychnine, Aminophylline, 
Donepezil 
(117) Acetylcholine 
Habenulae - 
Interpendnuclar 
nucleus 
 Aminophylline, NMDA, Kainic, 
Apomorphine, Emetine, Rolipram, 
Amitriptyline, Muscarine, 
 Strychnine, Bicuculine, Picrotoxin, 
Quinine, Amoxipine, Caffeine, Cis-ACPD, 
Nomifensine, SB205607, 
(118) Acetylcholine 
Tegmentum - 
Diencephalon 
 Aminophylline, NMDA, Kainic, 
Apomorphine, Rolipram, 
Amitriptyline, 
 PTZ, Strychnine, Bicuculine, Picrotoxin, 
Amoxipine, Bethanechol, Caffeine, Cis-
ACPD, Olanzapine, Physostigmine, 
SB205607, 
(118) Acetylcholine 
Torus 
semicircularis - 
Pretectum 
 Amitriptyline, Amphetamine, 
Bethanechol, 
 Strychnine, Bicuculine, Quinine, 
Theophylline, Caffeine, Muscarine, 
Tacrine, 
(118) Acetylcholine 
Diencephalon - 
Rhombencephalon 
 Kainic, Rolipram, Amitriptyline, 
 Strychnine, Bupropion, Donepezil, 
Bemegride, Bicuculine, Picrotoxin, 
Amoxipine, Caffeine, Ketoconazole, 
Muscarine, 
(116) Noradrenaline 
Cerebellum - 
Locus coeruleus 
, Bethanechol, Caffeine, Cis-ACPD, 
Cocaine, Ketamine, Ketoconazole, 
Muscarine, Nomifensine, 
Physostigmine, Donepezil, NMDA, 
Bemegride, Clozapine, Picrotoxin, 
Amitriptyline, Amoxipine, 
Amphetamine 
 Kainic, Theophylline, Apomorphine, 
Morphine, 
(116) 
Noradrenaline/ 
Dopamine 
Area postrema - 
Spinal Cord 
Yohimbine, Apomorphine, Cisplatin, 
Emetine, Morphine, Rolipram, 
Amitriptyline, Amphetamine, 
Bethanechol, Cocaine, Muscarine, 
Physostigmine, 4AP, Aminophylline, 
Bupropion, Donepezil, NMDA, 
Bemegride, Clozapine, Kainic, 
Theophylline,  
  
 
Table 4: from left to right: Column 2: The neurotransmitter present in the identified neurochemical pathway. 
Column 3: The two ROIs the neurochemical pathway connects. Column 4: Compounds that have a 
signficantly higher mean connectivity value between the two corresponding ROIs than control. Column 5: 
Compounds that have a signifcantly lower mean connectivity value between the two corresponding ROIs 
than water. 
Amitriptyline features heavily as amitriptyline causes a large increase in 
functional connectivity generally (see table 3). Moreover, dopamine agonists 
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such as cocaine and amphetamine do not appear to increase functional 
connectivity between the identified ROIs for dopamine. The only exception being 
between the posterior tuberculum and the Subpallium. Similarly, acetylcholine 
upregulators such as donepezil, tacrine, and physostigmine noticeably do not 
increase functional connectivity between ROIs connected by alleged 
acetylcholine pathways. 
Connections between the raphe superior and the spinal cord appear to have 
some sensitivity for serotonergic compounds. Cocaine, ketamine, nomifensine, 
amoxipine and amphetamine all increase functional connectivity between the 
regions and all are agonists of serotonin. However, the functional connectivity of 
this area was increased for a number of other compounds also. 
Drugs with effects on noradrenaline seemed to consistently increase functional 
connectivity in both the noradrenaline pathways with compounds such as 
bupropion, amphetamine and amoxipine. However, again relevant compounds 
appear beside a wide array of other compounds.  
Generally speaking this particular approach did not show that there were any 
specific functional connectivity values that were indicative of specific 
pharmacologies. It is on this basis that multivariate techniques were used, in to 
take into account all the parameters simultaneously, as opposed to the univariate 
approaches described above.  
 
Hierarchical clustering of Principal component scores 
PCA product 
I used a hierarchical clustering algorithm to produce a dendrogram, clustering 
together drugs with similar functional connectivity values or peak profile 
parameters in the zebrafish brain, based on their respective principal component 
scores (figure 8). To demonstrate that the principal component scores were 
accurately represented by the dendrogram and to highlight the way in which 
principal component scores represent compounds, the principal component 
scores of drugs that were closely linked in the dendrogram are shown in figure 7.  
As an example, CisACPD and bethanechol on the left-hand side of figure 7 are 
closely associated with one another in the dendrogram, (see figure 8). Similarly, 
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4-aminophenylsulfone and SNC80, on the right hand-side of figure 7 are closely 
associated, but the pair on the left and the pair on the right hand-sides are distinct 
from one another. These similarities and distinctions in figure 8 are mirrored in 
figure 7. 
 
  
Hierarchical Clustering of Functional Connectivity: Relation to Known 
Pharmacology 
4-Aminophenylsulfone and SNC80 were the two compounds deemed most 
similar in functional connectivity by the clustering algorithm (see figure 7). 4-
Aminophenylsulfone is an antibiotic with no known effect on brain function, 
conversely SNC80 is a delta opioid agonist. However, there is evidence to 
suggest that SNC80 has poor affinity to zebrafish delta opioid receptors and it 
seems in this case to have little effect in the zebrafish brain (119), thus explaining 
its close proximity to 4-aminophenylsulfone in this dendrogram. The 
antihistamine mizolastine is also clustered closely to both SNC80 and 4-
aminophenylsulfone. This is unsurprising as mizolastine has been shown to be 
free of the sedative effects often associated with H-1-recepter antagonists (120). 
Figure 7: Line graphs of the mean principal component scores. Grey outline is standard error of the mean of 
the principal component scores across all experiments of the respective class. The two compounds on the left-
hand side cluster together strongly and have highly similar mean principal component scores, as do the two 
drugs on the right. Comparatively comparing the left and right-hand sides there is relatively little similarity as 
evidenced by the difference in profiles exhibited. 
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The next two closely associated compounds were apomorphine and emetine, 
both drugs have emetic properties which may explain their close proximity 
(121,122). Cisplatin and kainic acid form a close-knit cluster with emetine and 
apomorphine. Cisplatin is also a powerful emetic which strengthens the 
suggestion that emetic drugs induce distinct functional connectivity patterns. 
(123). Conversely kainic acid is a glutamate agonist (124), however in the larval 
cultures for exposure via the medium it does not appear to be bioavailable and 
so is unlikely to elicit any pharmacological effect (see table 1).  
The medications amoxipine and olanzapine also have very similar functional 
connectivity patterns to one another. Amoxipine and olanzapine are used for 
treating depression and schizophrenia, respectively, and both compounds have 
effects on dopamine, serotonin and noradrenaline. Interestingly, while amoxipine 
is a serotonin and noradrenaline reuptake inhibitor (79), olanzapine is a serotonin 
and noradrenaline antagonist (64). In this context, it is counter intuitive that these 
two seemingly contradictory compounds associate so closely. However, 
amoxipine does also have some antagonistic effects on serotonin and 
noradrenaline receptors and it may be the case that these effects are accentuated 
in zebrafish (79).  
The illicit drug cocaine is the next most similar compound, in terms of functional 
connectivity, to amoxipine and olanzapine. Cocaine prevents reuptake of 
serotonin, noradrenaline and dopamine by inhibiting their associated transporters 
(125). Cocaine therefore shares some of its primary pharmacological actions with 
amoxipine which may explain the similar functional connectivity patterns. The 
cluster most closely associated with amoxipine olanzapine and cocaine includes 
the three compounds nomifensine, ketamine and ketoconazole. Much like 
cocaine, nomifensine is a dopamine reuptake inhibitor (102). Nomifensine is most 
closely associated with ketamine in the dendrogram. Ketamine is a drug with a 
large repertoire of pharmacological effects including N-methyl D-aspartate 
(NMDA) receptor inhibition (101), dopamine receptor agonism (126) and 
serotonin receptor agonism (127). The latter two effects may explain ketamine’s 
similarity in functional connectivity with drugs such as amoxipine, nomifensine 
and cocaine. Ketoconazole is the compound most closely linked to nomifensine 
and ketamine, despite being an antifungal with no recorded effects on dopamine, 
serotonin or noradrenaline (104).   
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Higher up in the dendrogram from the aforementioned clusters, is the pairing of 
cis-ACPD and bethanechol. Bethanechol is a parasympathomimetic which is 
pharmacologically and structurally related to acetylcholine (83). In contrast, cis-
ACPD is a potent NMDA receptor agonist (71). Both compounds induce a 
generalised increase in functional connectivity across the zebrafish brain (see 
table 3) but do so using different mechanisms of action. The next most closely 
associated drug to this pair is physostigmine, an acetylcholinesterase inhibitor. 
Much like bethanechol, physostigmine is a parasympathomimetic, and is 
Hierarchical Clustering of Functional Connectivity 
Amitryptyline
Picrotoxin
Bicuculline
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Tacrine
NMDA
Caffeine
Physostigmine
CisACPD
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Tetraethylammonium 
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Nomifensine
Ketamine
Cocaine
Olanzapine
Amoxipine 
Donepezil
Bupropion 
Pilocarpine
Yohimbine 
Clozapine 
Water
4-Aminopyridine
Morphine 
Emetine
Apomorphine 
Cisplatin 
Kainic acid 
Rolipram
Aminophylline 
Quinine 
Clonidine 
Bemegride  
Maprotiline
Strychnine  (Gly but not brain)
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Gabazine
Theophylline 
Mizolastine
SNC80
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Figure 8: Cluster dendrogram output of hierarchical clustering algorithm performed on functional connectivity 
data. Colours indicate broader pharmacological classes. 
Primary mechanism 
GABA inhibition
Modified noradrenaline and/or serotonin and/or dopamine (+ or -)
Major  Acetylcholine modulation (+ or -)
Glutamate  modulation (+ or -)
Opioid modulation 
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Histamine 
Potassium channel blocker
α-adrenoreceptor (+ or -)
Varied Primary Mchanism
MOA not clear 
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responsible for the stimulation of muscarinic acetylcholine receptors (62).  The 
cluster most closely associated to physostigmine, bethanechol and cis-ACPD 
also contains a muscarinic agonist, muscarine, suggesting there is some 
clustering of parasympathomimetic compounds (82). Muscarine is partnered 
most closely with tetraethylammonium, a compound that increases the length of 
action potentials by blocking potassium channels (128). Tetraethylammonium 
may have other properties that explain its similarity to muscarine, as 
tetraethylammonium is not a well understood compound. Directly adjacent to this 
pair is the illicit drug amphetamine. Amphetamine has a wide range of 
pharmacological effects including dopamine reuptake inhibition (129). 
Amphetamines dopaminergic activity may explain its similarity to muscarine, as 
stimulation of muscarinic receptors can initiate dopamine release (130).  
Interestingly, tacrine and NMDA for a cluster. This cluster is markedly distinct 
from all other clusters however this pair is mirrored in the cis-ACPD and 
bethanechol pairing. NMDA, like cis-ACPD, is a NMDA receptor agonist (131) 
and tacrine, like bethanechol, is an acetylcholine agonist (132). The pairing of 
acetylcholine agonists and NMDA receptor agonists is unexpected as they are 
two distinct pharmacological mechanisms however it may be explained as a 
reflection of the seizurogenic properties of the compounds. Drugs that increase 
acetylcholine activity have been implicated in seizurogenesis in rats (133), 
similarly NMDA agonism is known to be effective in generating seizures (134). 
Peak parameter clustering: relation to known pharmacology 
When clustering the peak parameters, the two most closely associated 
compounds were the water and cisplatin (see figure 9). This suggests cisplatin 
has little effect on zebrafish brain dynamics. Given that cisplatin is not typically 
considered a neurotropic drug it’s similarity to water conforms is what would be 
expected pharmacologically (135). The next two most closely associated drugs 
with cisplatin and water are kainic acid and emetine. Kainic acid, as mentioned 
above, does not appear in detectable quantities in the zebrafish brain (see table 
1), using the culture approach adopted, thus, its similarity with water is 
unsurprising. Emetine is closely paired with kainic acid and like cisplatin isn’t 
typically associated with any cognitive effects (97). The next most closely 
associated compound with the aforementioned four compounds is 4-
aminophenylsulfone, another drug without established effects on the central 
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nervous system (92). The next most closely allied pair contains the compounds 
ketoconazole and clonidine. Ketoconazole is an anti-fungal drug with no known 
brain effects, as such it would not be expected to induce changes in the zebrafish 
brain, thus explaining its relatively close localisation with water (14). Conversely, 
clonidine is an alpha-adrenergic agent that has well established effects on the 
brain and is known to localise in the CNS. By binding to a variety of alpha-
adrenergic receptors it has a plethora of effects including pain relief and reduced 
Figure 9: Cluster dendrogram output of hierarchical clustering algorithm performed on peak parameters. 
Colours indicate broader pharmacological classes. 
Hierarchical Clustering of Peak Parameters
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blood pressure (93). Clonidine may represent the boundary after which brain 
active drugs start to be present in the dendrogram.  
The next cluster positioned higher up the dendrogram from water and contains 
an assortment of serotonergic and dopaminergic active compounds. Of these, 
the pair of compounds with most similar peak parameters are ketamine and 
bupropion. Ketamine, among a range of other effects enhances descending 
inhibiting serotonergic pathways and inhibits reuptake of serotonin, noradrenaline 
and dopamine (136). Similarly, bupropion has inhibiting effects on serotonin, 
noradrenaline and dopamine reuptake (77). The next most similar compound is 
Table 3: from left to tight: compounds used in experiment, mean area under the curve, mean peak number, 
mean peak height, mean peak width, and mean peak seperation. All veargaes were calculated across all 
ROIs and all experiments of each class.  
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amoxipine, a tricyclic antidepressant that induces noradrenaline and serotonin 
reuptake inhibition (137). 
Adjacent to this cluster is a trio of drugs including: nomifensine, amphetamine 
and cocaine. All three of these compounds are involved in either dopamine 
reuptake inhibition and or direct dopamine agonism (103,138,139). 
Amphetamine and cocaine both also increase synaptic neurotransmission of 
serotonin and noradrenaline (138,139). Notably, nomifensine and apomorphine 
occupy different parts of the dendrogram, despite their similar chemical 
structure. However, this is perhaps not unexpected as while both compounds 
upregulate dopaminergic neurotransmission, they have contrasting effects on 
the adrenergic system. Nomifensine is a noradrenaline reuptake inhibitor (140) 
and thus is responsible for increasing adrenergic synaptic transmission while 
apomorphine is thought to have antagonistic effects on adrenergic receptors 
(141). 
Of the five-remaining serotonergic, dopaminergic or noradrenergic compounds 
apomorphine, clozapine and olanzapine all have some form of serotonergic, 
adrenergic or dopaminergic antagonism and thus their absence, from the 
aforementioned cluster of six mood enhancing compounds, makes 
pharmacological sense (95,142–144).  
 Moreover, maprotiline, which is also absent, has only weak dopaminergic and 
serotonergic activity (78). Amitriptyline is the only remaining drug that should 
potentially cohabit this cluster due to its serotonin and noradrenaline reuptake 
inhibition (80). Given that amitriptyline is not remotely similar, in terms of its 
peak profiles or indeed its functional connectivity values, to any other compound 
it could be argued that it is an anomaly. Adjacent to the cluster of mood 
elevating compounds, described above is another tightly knit group of 
compounds consisting of clozapine, mizolastine, SNC80, gabazine and 
maprotiline. This cluster contains a diverse array of pharmacologies. Clozapine 
is an atypical antipsychotic medication which is an antagonist of dopamine, 
serotonin and adrenergic receptors (143). SNC80 and mizolastine, clozapine’s 
closest allies, are a μ–δ opioid receptor agonist and antihistamine respectively 
(96,145). Maprotiline and gabazine also form a tight pairing and are an 
adrenergic reuptake inhibitor with weak action on serotonin and dopamine 
transporters and a GABAA antagonist respectively (78,146). While they do have 
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discordant pharmacologies gabazine and maprotiline both have relatively poor 
bioavailability in embryo-larval cultures (see table 1) and thus in the zebrafish 
brain which may explain their pairing.  
 
Peak parameter clustering results in relation to seizurogenic properties 
Moving up the dendrogram from maprotiline, the following 14 compounds have 
little pharmacologically validatable clustering. At the point of PTZ, however, there 
again appears to be some clustering of acetylcholine modulating compounds. 
Strychnine, PTZ and pilocarpine form a cluster however a reasonably well spread 
one. PTZ and strychnine are both seizure inducing compounds however via 
different modes of action. PTZ inhibits GABAA to reduce inhibitory 
Figure 10: Cluster dendrogram output of hierarchical clustering algorithm performed on peak parameters. 
 
Seizure Generating Potential
Potentially Seizure Generating
Not Potentially Seizure Generating
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neurotransmission and initiate seizures (147). Conversely strychnine induces 
seizure via glycine inhibition in the spinal cord (148). Pilocarpine, in contrast to 
strychnine, is a muscarinic agonist (81), rather than a acetylcholine antagonist 
(149).  Sitting above pilocarpine in the dendrogram is a quartet of compounds: 
donepezil, bemegride, tacrine and physostigmine forming a cluster, however 
each member of the cluster is relatively far away in euclidean space. Of these 
four compounds, all except bemegride are acetylcholinesterase inhibitors (150–
152).  
At the very top of the dendrogram a single cluster of three compounds reside: 
NMDA, aminophylline and 4-Aminopyridine. All three of these compounds have 
distinct pharmacologies and indeed the dendrogram places them reasonably 
separate from each other in euclidean space. While they are not similar 
pharmacologically they all have well established seizurogenic properties 
(84,153–155). 
Using the peak hierarchical clustering approach, drugs with seizure generating 
potential were highlighted to assess if seizurogenic compounds showed some 
clustering. Upon observation it seemed that they were, at least to some extent. 
All the non-seizurogenic drugs occupied a single large cluster at the bottom of 
the dendrogram (figure 10). All the sub-clusters within this large cluster were less 
than two units in euclidean space away from each other (see figure 10). However, 
there are several seizurogenic compounds within this cluster. Of these some 
have low uptake into the zebrafish CNS including picrotoxin, maprotiline, 
gabazine and kainic acid (Table 1). Additionally as SNC80 has poor affinity for 
zebrafish delta opioid receptors (119) it is unlikely to demonstrate its seizurogenic 
potential (156). Moreover, there are no uptake data for theophylline and thus it is 
also possible that low bioavailability is an issue. Aside from theophylline, all the 
remaining seizurogenic drugs that reside within this cluster are serotonin, 
dopamine and noradrenaline inhibitors. These mood elevating compounds 
cluster together regardless of seizurogenic potential and seem to elicit spatially 
specific peak profiles.  
Functional connectivity clustering results in relation to seizurogenic properties 
Clustering of seizurogenic compounds was less specific when clustering was 
performed on the connectivity parameters. There was some clustering of 
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seizurogenic drugs at the top of the dendrogram (figure 11), including 
amphetamine and Picrotoxin, two compounds that clustered with non-
seizurogenic compounds in the peak profile dendrogram. However, generally 
speaking, non-seizurogenic drugs were spaced fairly evenly throughout. It is clear 
that while functional connectivity shows some clustering of seizurogenic 
compounds it is, generally speaking, an inferior method for assessing the 
seizurogenic properties of compounds relative to assessing the peak profiles. 
 
Differences between peak and functional connectivity analyses 
Hierarchical Clustering of Functional Connectivity 
Amitryptyline
Picrotoxin
Bicuculline
SB205607
Tacrine
NMDA
Caffeine
Physostigmine
CisACPD
Bethanechol
Tetraethylammonium 
Muscarine
Amphetamine 
Ketoconazole
Nomifensine
Ketamine
Cocaine
Olanzapine
Amoxipine 
Donepezil
Bupropion 
Pilocarpine
Yohimbine 
Clozapine 
Water
4-Aminopyridine
Morphine 
Emetine
Apomorphine 
Cisplatin 
Kainic acid 
Rolipram
Aminophylline 
Quinine 
Clonidine 
Bemegride  
Maprotiline
Strychnine
PTZ
Gabazine
Theophylline 
Mizolastine
SNC80
4-Aminophenylsulfone 
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Mean Euclidean Distance 
Figure 11: Cluster dendrogram output of hierarchical clustering algorithm performed on connectivity parameters. 
The colours of compounds indicate seizurogenic potential, with compounds in red being potentially seizurogenic, 
and those in green being non-seizurogenic 
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Water and 4-Aminopyridine cluster tightly together when analysed based on their 
respective functional connectivity values. However, when clustered based on 
their peak profiles the two compounds were distinct from one another (see figure 
10 and 11). Similarly, water and cisplatin clustered closely based on their peak 
parameters but were distinct from one another when compared using their 
functional connectivity values (see figure 10 and 11). Figure 12 (top of next page) 
highlights the distinction between utilising peak parameters extracted from the 
time series and functional connectivity. While some compounds may have closely 
related functional connectivity this does not necessarily translate to closely 
related functional connectivity and vice versa. These significant distinctions 
between the two sets of parameters underlies the motivation for analysing them 
separately.   
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Discussion 
Of the analytical techniques used the most effective was the clustering approach. 
Similar multivariate clustering approaches have been used previously to 
successfully cluster cognition enhancing compounds based on parameters 
extracted from cortical EEG oscillations (8). The evidence from EEGs in mice 
suggests certain drugs elicit distinct temporal activation patterns and that analysis 
of brain dynamics over time could provide useful biomarkers for specific 
pharmacodynamics. The study describe here utilises calcium imaging techniques 
Figure 12: On the left-hand side: Representative time-series of all 42 ROIs. ON the right-hand side: Mean functional 
connectivity values across experiments of individual classes (with outliers removed). The x-axis here represents every 
possible pair of ROIs.   
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for detection of brain activity and thus has a far greater emphasis on spatial 
information than temporal. Comparison of the spatially specific parameter 
clustering with the mean parameter values suggest that spatially specific 
temporal information is highly informative for profiling drugs and that spatial 
element is of particular importance. 
Of the two sets of parameters, peak profiles and functional connectivity data, 
peak profiles seemed to provide the most useful data, both in terms of identifying 
seizurogenic compounds and identifying pharmacology. In terms of the functional 
connectivity data, it may be that for some compounds the pharmacological 
signatures were overridden due to hyperexcitation, induced by the high 
concentrations used for some compounds. Despite this the functional 
connectivity data were not totally unsuccessful; there was some clustering of both 
antidepressant and seizurogenic compounds.  
During analysis of the peak profiles, five of the six drugs most closely associated 
with water would be considered unlikely to induce any significant cognitive effect 
based on their respective pharmacologies, suggesting that non-neurologically 
active compounds could be consistently identified using this approach. Moreover, 
the entire upper half of the dendrogram, contained a cluster exclusively populated 
with seizurogenic drugs. 
Aside from an aptitude for identifying non-seizurogenic compounds, the peak 
profiles displayed an efficacy for clustering compounds based on their 
pharmacologies. An interesting example of this is the clustering of bupropion and 
ketamine. Bupropion is a well-established antidepressant drug and ketamine has 
come to the forefront in more recent years as an alternative antidepressant that 
is effective in treating patients with major depressive disorder, including those 
resistant to other medications (56). Including this pair, there is a cluster of six 
drugs that have a mixture of dopaminergic, noradrenergic and serotonergic 
agonistic effects, all of which could be classified as mood elevating compounds. 
The functional connectivity analyses contained a similar cluster containing a 
number of the same compounds, however it was not as extensive nor as tightly 
knit as in the case of the peak profiles.  
It seems, therefore, that mood elevating compounds, such as recreational and 
antidepressant drugs, elicit very specific and similar spatio-temporal patterns in 
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the zebrafish CNS. The approaches detailed here could therefore have some 
implication in the categorisation and identification of drugs for treating 
depression, a disease for which current therapeutics have a number of concerns 
in terms of efficacy and toxicity (157). 
Peak profile parameters, unlike functional connectivity, provide a measure of the 
magnitude of activity. This is of particular relevance in the case of identifying 
seizurogenic compounds, as seizures very much derive from hyperexcitation 
(158), thus a measure of magnitude should confer greater differentiation between 
seizurogenic and non-seizurogenic compounds. Moreover, differences in 
magnitude are translated well in the analyses as euclidean distance is sensitive 
to these differences. In terms of pharmacology magnitude is also relevant as 
some pharmacologies will likely increase the number of action potentials in 
specific areas, therefore spatially specific increases in magnitude likely confer 
useful information for modelling of pharmacodynamics.  
While the lack of information, in terms of magnitude, conferred by functional 
connectivity could be perceived as a flaw, it does allow for analyses to be 
performed without concerns that slight variations present in the model organism 
may have a detrimental effect on the results. This is of particular relevance, in 
this case, due to the lack of a within experiment control that could account for 
variation between animals or indeed batches of animals. As such, variations in 
terms of baseline fluorescent intensity are more difficult to account for as 
removing the mean linear trend doesn’t fully mitigate the heterogeneity between 
animals. As functional connectivity analyses compare different ROIs from the 
same animal to one another, differences in overall magnitude between animals 
is mitigated.  
In addition, there are distinction in terms of the spatial information provided by 
the two sets of parameters. The peak parameters consider the spatial element of 
the data but using summarised representations of the time series. Conversely 
functional connectivity considers the whole timeseries point by point and 
consequently provides a more complete representation of the spatio-temporal 
patterns, however does not provide direct information about the precise temporal 
dynamics, for example the size and amplitude of spikes. 
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Moreover, it is possible that functional connectivity could perform better in terms 
of representing pharmacology were hyperactivity not an issue and concentrations 
were kept at effective but non-hyperactive levels. It should be noted that for this 
animal model within experiment controls are not always possible, as drug 
exposure times can be long, and fish may not stay alive and healthy in agar for 
long enough for experiments to be performed. In this respect functional 
connectivity is advantageous and while it performed poorly in this study it should 
not be written off on this basis. 
Chapter Three: Classification learners. 
Introduction 
In the previous chapter it was identified that potentially seizurogenic compounds 
cluster towards each other when compared based on their peak profiles. 
Therefore, in this chapter I set out to identify if a classification model could be 
trained that recognises seizurogenic compounds based on their peak profiles, 
and thus build a framework that could be used to separate seizurogenic from 
non-seizurogenic compounds. The overall aim is to create a model that can 
accurately identify seizurogenic compounds based on the peak profiles of 
unseen data. That is to say, were identical experiments performed on an 
unknown or novel compound and identical parameters extracted from said 
experiments, the data could be fed into the model and the model would provide 
a reliable assessment of whether that compound has the potential to be 
seizurogenic or not.  
In order to do this, I utilised the MATLAB built in classification learner tool box 
(159) to generate and test a number of different machine learning algorithms. 
Machine learning algorithms vary greatly in terms of the kind of data they are 
adept at classifying, because different approaches depend on different 
assumptions of the data (160) (see below for more detail). Given the lack of 
information on the problem at hand I decided to test multiple classifiers to see 
how they performed against each other. Three different discriminative models 
were chosen for this task: a shallow neural network (NN), a support vector 
machine (SVM) and a logistic regression. The models were chosen because 
they are three models widely used in science and because they each have very 
different ways of addressing the classification problem. 
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Classification algorithms can be highly accurate predictive models. In past 
studies, utilising data generated from structural MRI scans, SVMs have been 
able predict the clinical response of patients to antidepressant drugs with up to 
89% accuracy, prior to the initiation of treatment (161). Similarly, EEG data in 
conjunction with machine learning techniques, has been used to predict 
responses to clozapine therapy with up to 85% accuracy in an independent test 
group (162). 
In addition to drug response prediction, machine learning approaches have also 
been used in the area of drug discovery. Novel compounds can be compared to 
known compounds and biological targets, based on their structural similarity, 
using parameters such as molecular properties, topological descriptors and 
pharmacophore fingerprints. Using machine learning techniques in conjunction 
with these measures can provide valuable insight into the applications of novel 
compounds (163). Such approaches provide information about compounds very 
early on in the drug creation process and are therefore an invaluable tool. 
Later on, in the drug development process, machine learning can provide 
insight into the effects of drugs in vivo. Machine learning based analysis of brain 
networks has proved effective in differentiating drugs based on their in vivo 
effects. In one such study, fMRI scans were performed on healthy volunteers 
exposed to two compounds with distinct pharmacologies. The image data 
obtained was analysed using machine learning approaches and the resulting 
model could sensitively differentiate between the two compounds and a placebo 
(164). Machine learning algorithms have also been applied to behavioural 
assays in zebrafish as a predictor of drugs pharmacological profiles (165). 
Given the efficacy of machine learning approaches on similar kinds of data sets, 
in the area of drug discovery, and the ease with which such tools can be applied 
to new data, machine learning algorithms were applied to differentiate between 
the seizurogenic and non-seizurogenic compounds in our data set.  
The following sections give an overview of the principals necessary to 
understand machine learning. In addition, I describe intuitively how each of the 
algorithms used in this thesis function. This is not only to provide the reader with 
understanding but also to highlight how varied machine learning algorithms are 
and in what contexts particular types of algorithm flourish. 
Page | 54 
 
Training and test data 
Classification learners are trained using training data. Training data is given to a 
classification learner in conjunction with information regarding how the data 
should be classified (i.e. the ground truth). Unseen test data, with known 
classes, is subsequently used to test the classifier to see how often the 
classifier classifies correctly (166). 
For example, to generate a model that predicts whether or not a student was 
going to pass an exam a previous cohort of students that sat the exam could be 
analysed, with variables such as number of hours studied, previous test scores 
in other subjects, numbers of hours of sleep a night etc. extracted. A parameter, 
in this context, is any information that can be extracted from a data set that is 
potentially predictive of the outcome. The cohort could then be split into training 
and test sets, with half the students that passed the exam and half the students 
that failed the exam contained in each set. 
The extracted parameters would be run through a training algorithm for the 
model in conjunction with the known output: whether or not that student passed 
the exam.  This is what is known as supervised learning. That is to say, a 
classification learner is provided with the data to be classified and provided with 
the correct classification for each piece of input data.    
Once the classifier has been ‘trained’ it is necessary to ‘test’ the classifier to see 
if it can effectively classify new data. This simply means providing a classifier 
with the test set. The classifier is then used to predict the classification of each 
student in the test set: whether or not they pass or fail the exam. Because the 
exam scores of the students are known the accuracy of the classification 
learner can be calculated. 
 
 
Support Vector Machine 
Extending upon the exam pass example in the context of SVM, for this 
example, I envisage two parameters: the test scores from two previous exams. 
First the data would be split into test and training sets. Then each of the 
individuals, from the training data, are mapped onto data points in a feature 
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space in this case points on a two-dimensional plot (one dimension for each 
parameter). Subsequently, a dividing line is drawn, in two dimensions, between 
individuals that fall into the different classifications; in this case individuals that 
pass an exam and individuals that fail. 
The position of this dividing line is decided as follows: lines are drawn along the 
data points from each classification that are closest to the data points from the 
opposing class, these are known as the support vectors. A line is then drawn 
that is equidistant from each support vector and that maximally separates the 
classifications. Considering the application of this algorithm to higher 
dimensional problem, the line is called a hyperplane (167). 
 
 
Figure 63: The blue circles represent students who pass the test. The red circles represent students who 
fail the test. The x and y axes are the parameters, in this case previous test scores. The line separating 
them is the hyperplane. When a new student’s test scores are input into this model and are above the 
hyperplane they will be classified as a student who passes the exam. 
 
When the test data is input into the constructed support vector machine it too is 
mapped into the feature space and the side of the line it falls on dictates its 
classification.  
For the example above, two parameters were used for ease of visualisation. 
However this approach can be applied to data sets with a huge number of 
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parameters. The number of dimensions in the feature space is simply increased 
to be equal to (or higher than – in the case of kernel functions) the number of 
parameters. The parameters then act as co-ordinates for each of the data 
points in the multidimensional feature space.  
The advantage of SVMs is they can be applied to very high dimensional data 
and don’t necessarily require a large number of data points. In fact, the only 
data points that influence the outcome in an SVM are those that influence the 
positions of the support vectors.  
Now the hyperplane is easy to draw in the case of linearly separable data such 
as in figure 13, because the data are completely separated in their feature 
space. Thus, the position of the hyperplane is easily dictated. However, if this is 
not the case, such as in figure 14, then generating the hyperplane becomes 
more complex.  
 
Figure 14: The blue circles represent students who pass the test. The red circles represent students who 
fail the test. The x and y axes are the parameters, in this case previous test scores. There is overlap 
between the blue and red circles, thus these data are not linearly separable. 
Given that I don’t expect most real-world data to be perfectly linearly separable 
it is necessary to employ kernel functions. Kernel functions represent the 
distance between data points in higher dimensional space. They essentially 
take the parameters used to map the data points and combine them to form 
additional parameters. The goal of this process is to take the data points that 
aren’t linearly separable and map them into a higher dimensional space where 
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they are (167). This allows the computation of a hyperplane in data sets that are 
not linearly separable. 
Neural Networks 
Neural networks come in many shapes and sizes, the one used in this study is 
a simple single layer feed forward neural network (168). Neural networks have 
input, hidden and output layers. In each layer there are a number of ‘neurons’ 
each of these neurons has a connection to every single one of the neurons in 
the subsequent and previous layer. The number of neurons in the input layer is 
equal to the number of parameters in the data, the hidden layer has as many 
neurons as the experimenter chooses, and the output layer has as many 
neurons as there are classifications. In the test pass example, this would mean 
that both the input layer and output layer would have 2 neurons, due to there 
being two parameters (two past test results) and two classifications (pass or 
fail).  
The strength of each of the connections between neurons are decided by the 
‘weights’ and ‘biases’. Essentially, the weights and biases are just co-efficients 
in a regression equation. The weights and bias initially are randomly selected, 
but as training data is fed into the neural network the weight and biases are 
changed as more information is made available and the network learns. This is 
achieved using an algorithm called back-propagation. Back-propagation works 
by changing the weights and bias in response to how correctly the neural 
network classifies the training data. The training data is fed into the neural 
network multiple times and on each iteration the weights and biases are 
modified by back propagation to increase the accuracy of the output (169). 
Unlike SVMs, NNs use all of the data provided to inform the weights and biases. 
NNs function best when the n-number is significantly higher than the number of 
parameters. In the test pass example this would mean a significantly higher 
number of students relative to past test results. Conversely SVMs work equally 
well, regardless of this ratio, for this reason SVMs can perform significantly 
better in some contexts. 
When test data is fed into the network, the size of the output of each of the input 
neurons is influenced by the size of each of the parameters of the test data. The 
output of each of the input neurons is fed forward into every neuron in the 
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hidden layer, which subsequently is fed forward into the output layer. The output 
provided by the output layer is calculated based on the input received from the 
hidden layer. The input received by the output layer is therefore influenced by 
the weights and biases, in the hidden layer, calculated by the training algorithm 
and the parameters of the test data. 
The output layer provides a number between 1 and 0 for each classification, 
and the sum of all the outputs is equal to one. The values provided by the 
output neurons give the relative probability that each output is the correct 
classification based on the training data provided. In the test pass scenario, it 
would provide two numbers, one giving the probability of a pass, and one giving 
the probability of a fail. The sum of these two numbers would be equal to one. 
Binary Logistic regression 
The binary logistic regression provides probabilistic prediction of categories. It 
does this by generating an s-shaped graph for each individual parameter. 
Training data for each of the parameters are placed on a graph based on the 
category they represent and the value they have for the corresponding 
parameter. Their position on the graph dictates the shape of the s-shaped curve 
which is subsequently used to confer the probability of the unknown test data 
belonging to one of two output categories. 
The probabilistic outputs for each individual parameter are combined to 
generate an overall probability of the outcome for each test example. Logistic 
regressions are often inaccurate in situations where there is a large ratio of 
predictor parameters to observations and if parameters are highly correlated 
(170). 
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Figure 15: An example of what a logistic regression curve for an individual parameter looks like. Each of 
the points represent a different observation. Observations of students who passed the exam are placed at 
the top and observations of students who did not pass are placed at the bottom. Their position along the x-
axis is relative to their value for the corresponding parameter. Test data have a probabilistic output given 
by the y-axis dependent on their parameter value. In this example 3 hours of studying would relate to an 
approximately 59% pass probability (171). 
 
Methods 
Data input 
Data acquisition, image processing and peak parameter extraction were 
performed as detailed in chapter two. Again, input data were limited to 
experiments of more than one hundred and ninety-seven frames in length. 
Kainic acid was excluded from analyses due to not being present in measurable 
quantities within the animals (see table 1). For these analyses PCA was not 
performed in order to keep the number of parameters identical in both the 
training and test sets. Outlier removal was performed in an identical manner to 
that describe in chapter two with the exception that it was performed directly on 
the vectors of peak parameters as opposed to the principal component scores. 
The input data were therefore a vector of peak parameters for all the 
experiments remaining after outlier detection was performed. Each experiment 
is therefore a vector of three hundred and seventy-eight peak parameter 
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parameters consisting of the standard deviation and mean of each peak 
parameter for each ROI.  
 
Training and test data – For informing model selection. 
Initially, training and test data input was selected in a leave one out training and 
testing algorithm (see figure 16). Each model was trained on all of the data 
except one compound and then subsequently each of the trained models was 
tested using the compound that was left out of the original training data set. This 
was done in order to assess how well each trained model performs on each 
compound, when the model has been trained entirely independently of that 
All Classes — 42 
compounds + control 
Training set — 41 compounds + 
control 
Test set — 1 
compound 
Quadratic 
SVM 
Shallow 
Neural 
Network 
Logistic 
Regression 
Extract performance data for 
each model on test set: 
accuracy false positive rate, 
false negative rate. 
Train 
Models 
Restart process, 
selecting a 
different test 
compound 
Test Models 
Figure 16: Schematic outlining the leave one out approach used for testing each model’s 
performance. Allows all of the classes to be tested on each type of model.  
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compound. Once a model has been trained and tested using the ‘left out’ 
compound, the model is discarded. A new model is then trained using a setup in 
which a different compound is left out and subsequently used to test the trained 
model. The performance information generated for each model, in the form of 
its sensitivity, specificity and accuracy was used to gain a preliminary 
understanding of which model would be the most appropriate choice for the 
data. Sensitivity was calculated as the percentage of seizurogenic compounds 
classified as seizurogenic, specificity was the percentage of non-seizurogenic 
compounds classified as non-seizurogenic and accuracy was the overall 
proportion of compounds correctly classified. 
Given the large number of classification models available, this approach was 
utilised to inform the choice of model to use on randomised training and test 
sets. Moreover, the ‘leave one out’ approach allowed machine learning 
algorithms to be tested in the situation where a maximum amount of training 
data is available. Note that I expect to significantly expand on the amount of 
data available in the future.  
Training and test data - For model generation. 
After using the leave one out approach, to compare the efficacy of the different 
models for categorising the data, a randomised approach was utilised in order 
to provide an indication of the possible generalisability of the selected model. In 
this stage, the same data were split in two. Non-seizurogenic compounds were 
split: half into a training set and half into a test set. Seizurogenic compounds 
were also split: half into a training set and half into a test set.  
Training model support vector machines 
One of the models trained and tested was a support vector machine. This 
model was built using the default settings in MATLABs inbuilt classification 
learner toolbox. A quadratic support vector machine was trained by first 
mapping the experiments into multidimensional feature space based on their 
parameter values. A line, or ‘hyperplane’ was then placed between the 
experiments, in the multidimensional space, that fell in the space that 
maximised the distance between the two classifications: seizurogenic and non-
seizurogenic. Hyperplane generation was achieved using a second polynomial 
kernel function. As mentioned previously kernel functions are used to help find 
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the hyperplane in data that isn’t easily separable. In the internal model building 
algorithm, the SVM was tested for overfitting using a k-fold cross-validation 
algorithm with its own, internal hold out group. During the cross validation 
process data was randomly partitioned into five equal sized sub samples, each 
of which was used as the validation set for each iteration of the cross-validation 
process. This allowed the hyperplane to be optimised, ensuring that the SVM 
will perform accurately on new data sets. 
Training model neural network  
A two-layer feed-forward neural network was trained, with sigmoid hidden and 
softmax output neurons. The sigmoid function in the hidden layer neurons takes 
the weight and bias produced when training a neural network and coverts their 
output into a continuous spectrum between 1 and 0. The sigmoid function 
therefore provides a continuous measure of output for each of the hidden layer 
neurons. Moreover, the sigmoid function has an easily calculable derivative that 
can be used by the back-propagation algorithm to inform the changes in the 
weights and biases of the neural network that ultimately dictates its outputs. 
The softmax function receives outputs from all the neurons in the hidden layer. 
It then takes the output of the hidden layer of the neural network and puts it into 
a vector of values between zero and one, the sum of which add up to one.  The 
idea behind this is that each element of the vector represents a corresponding 
output and the size of the number is relative to the probability that the output is 
true. The softmax output neurons are therefore used to represent a categorical 
distribution of the output of the neural network. 
The model was trained with scaled conjugate backpropagation in a supervised 
learning process. There were five hundred neurons in the hidden layer. 
Although this large number of neurons could potentially lead to overfitting, the 
cross-validation steps in the training algorithm are designed to counter this. As 
such some neurons will have little to no input on the output the model but as 
this classification procedure is not computationally heavy it will have little impact 
on the overall procedure. 
Overfitting was prevented in the training algorithm by randomly splitting the 
training data into training, test and validation sets. The training algorithm used 
the validation set to test the performance of the model against unseen data to 
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ensure the models generalisability to new data. When the validation set error 
begins to rise, indicating overfitting, the weights and biases of the model were 
saved for when the validation set error is at its minimum. The test set error was 
not used during training however it was used to scrutinize varied models. The 
training, test and validation sets were selected by randomly splitting the training 
data in a ratio of 0.7:0.15:0.15 respectively. The performance of the network 
was tested using cross-entropy.   
Training Logistic regression model 
A generalised linear model was fitted to all of the training data. A ‘logit’ link 
function was used in order to generate probabilities for each of the 
classifications. Similar to the support vector machine the training algorithm 
involved k-fold cross validation, partitioning the training data into five equally 
sized random ‘k-folds’ which were used to help prevent the model from being 
subject to overfitting.  
Calculating performance of models on independent test sets 
Once each model was trained, the test data were run through each model. The 
following applies to both the leave one out training/test data and the randomly 
selected training/test data.  
Once constructed, the models provided an output for each experiment or 
‘observation’ provided in the test data. For the SVM the output was binary, i.e. 
for each experiment there was either an output of ‘yes this experiment is 
seizurogenic’ or ‘no this experiment is not seizurogenic’. In the case of the NNs 
and logistic regression the output was probabilistic. The NN gives two values 
between zero and one for how likely each experiment is from each class – 
seizurogenic or non-seizurogenic. In the case of logistic regression, it provides 
a single value for how likely the test data were seizurogenic. For both sets of 
outputs, in order to quantify the performance of the classifier a threshold of a 
half was applied to decide which output the classifier had chosen. That is to 
say, if the probability output for an experiment to be seizurogenic was more 
than a half then that experiment was considered seizurogenic. 
The performance of the models was calculated with respect to how effectively 
they could detect seizurogenic compounds. Compounds which had more than 
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half of their corresponding experiments classified as seizurogenic were 
considered to have been classified as seizurogenic overall. Compounds which 
had more than half of their corresponding experiments classified as non-
seizurogenic were considered to have been classified as non-seizurogenic. 
Compounds which had exactly half of the corresponding experiments classified 
as (non)seizurogenic were considered to be undecided, and therefore were 
considered misclassified overall. 
Seizurogenic compounds were considered ‘positive’ test results, thus true 
positives were seizurogenic compounds that were classified as seizurogenic. 
The sensitivity was calculated as the true positive rate and the specificity was 
calculated as the true negative rate. Accuracy was calculated as the percentage 
of compounds correctly classified overall. 
Leave one out vs random selection  
It is worth noting that the sensitivity, specificity and accuracy figures attained 
during the leave one out testing protocol are not for any specific model but 
rather an assessment of the utility of the algorithm. As previously mentioned, 
during the leave one out testing protocol multiple models are trained for each 
machine learning algorithm, this was done in order to assess how machine 
learning algorithms performed when provided with the maximum amount of 
training data. However, this protocol can give no information on the 
generalisability of each of the models as the amount of test data used on each 
model is insufficient. 
In order to generate and better interrogate a usable model it was necessary to 
randomly split data in half. The specificity, sensitivity and accuracy figures 
generated using this approach were specific to a single model for each of the 
algorithms used.   
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Results 
SVM performance 
Using the leave-one out testing protocol the trained SVM classified most non-
seizurogenic compounds reasonably well with 85% of the compounds that are 
non-seizurogenic having the majority of their experiments classified as non-
seizurogenic (see table 6). There were two non-seizurogenic compounds that 
were misclassified as seizurogenic: nomifensine and ketoconazole.  
Of the seizurogenic compounds used as test data approximately 30% were 
misclassified as non-seizurogenic. Of these picrotoxin, bicuculline and gabazine 
had poor uptake into the zebrafish CNS – with 1, 2 and 1.03% uptake 
respectively. Clozapine, maprotiline, SNC80, theophylline, amoxipine, cocaine 
and tetraethylammonium were also misclassified by their corresponding SVMs. 
Of those with good or unknown uptake into the zebrafish larvae: theophylline, 
maprotiline, SNC80, clozapine, cocaine, and amoxipine also clustered with non 
seizurogenic compounds during hierarchical clustering (see figure 10). Of the 
seizurogenic compounds that clustered with non-seizurogenic compounds 
during hierarchical clustering of peak profiles, amphetamine and bupropion are 
the only two that have been correctly classified as seizurogenic by their 
corresponding SVMs. There is a noticeable similarity between the hierarchical 
clustering outputs and the outputs of the SVMs which suggests the SVMs are 
effectively classifying the data and that perhaps it is the data driving the 
misclassification, due to issues with things like bioavailability and receptor 
Table 6: Each of the classes named were used to test an SVM that was trained on all the 
remaining classes. From left to right column one: Seizurogenic compounds classified as 
seizurogenic. Column two: Non-seizurogenic compounds that were classified as non-
seizurogenic. Column three: seizurogenic compounds that were classified as non-seizurogenic. 
Column four: non-seizurogenic compounds classified as seizurogenic. Column five: the sensitivity 
of this modelling approach for seizurogenic compounds. Column six: the specificity. Column 
seven: the overall accuracy.  
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affinity, as opposed to the choice of machine learning algorithm. It is worth 
noting that misclassifications are based on if compounds are considered 
seizurogenic based on the literature from humans and mammalian models as 
opposed to what is known in fish. In this sense misclassifications rates are 
effected to some extent by limitations relating to the experimental model, as well 
as the algorithm in question. 
Neural network performance 
The trained NN classified most non-seizurogenic compounds reasonably well 
with 85% of the compounds that are non-seizurogenic having the majority of 
their experiments classified as such (see table 7). The two compounds that 
were misclassified were nomifensine and mizolastine. Nomifensine was also 
misclassified by the SVM classifier.  
Of the seizurogenic compounds used as test data approximately 66% were 
classified correctly by their corresponding NN. NNs were therefore marginally 
less sensitive for detecting seizurogenic compounds, than SVMs, when tested 
using the leave one out approach. Of the compounds misclassified by the NNs, 
strychnine, muscarine, bupropion and bemegride were correctly classified by 
SVMs. However, the NN approach correctly classified tetraethylammonium, 
clozapine and amoxipine where the SVM did not. Both sets of models 
misclassified gabazine, maprotiline, picrotoxin, SNC80 and theophylline. 
Table 7: Each of the classes named were used to test an NN that was trained on all the remaining 
classes. From left to right column one: Seizurogenic compounds classified as seizurogenic. Column two: 
Non-seizurogenic compounds that were classified as non-seizurogenic. Column three: seizurogenic 
compounds that were classified as non-seizurogenic. Column four: non-seizurogenic compounds 
classified as seizurogenic. Column five: the sensitivity of this modelling approach for seizurogenic 
compounds. Column six: the specificity. Column seven: the overall accuracy.  
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The NNs had a classification accuracy of 71% when using the leave one out 
approach to test the efficacy of the model, marginally less than the SVM 
classifier at 74%. 
Logistic regression performance 
The logistic regression classifier was the poorest performing classifier on non-
seizurogenic compounds, classifying 77% of non-seizurogenic compounds 
correctly (see table 8). This equates to one additional misclassification relative 
to the SVM and NN approaches. Again, nomifensine is misclassified, as is 
mizolastine. 4-aminophenylsulfone is also misclassified despite being correctly 
classified by the other two approaches.  
Of the seizurogenic compounds approximately 55% were classified as 
seizurogenic by their corresponding logistic regression. This is a significant 
decrease in the classification rate of seizurogenic compounds compared to the 
other two approaches. Of the compounds misclassified pilocarpine, bicuculline, 
amitriptyline and bethanechol were only misclassified by logistic regression and 
were correctly classified by the other classifiers.   
Correctly classified 
Seizurogenic Compounds
Correctly classified Non-
seizurogenic compounds
Incorrectly classified 
Seizurogenic compounds
Incorrectly classified Non-
seizurogenic compounds
Sensitivity Specificity Accuracy
4-Aminopyridine,   
Pentylenetetrazol,   
Strychnine,  Aminophylline,  
Donepezil,  NMDA,  
Amoxipine,  Amphetamine,  
Caffeine,  CisACPD,  
Muscarine,  Olanzapine, 
Physostigmine  
SB205607,  Tacrine,  
Tetraethylammonium,
 Clonidine,  Quinine,  
Yohimbine,  Apomorphine,  
Cisplatin,  Emetine,  
Morphine,  Rolipram,  
Ketamine,  Ketoconozole,
 Pilocarpine,   Bupropion,  
Bemegride,  Bicuculine,  
Clozapine,  Gabazine,  
Maprotiline,  Picrotoxin,  
SNC80,  Theophylline,  
Amitriptyline,  Bethanechol,  
Cocaine, 
 4-Aminophenylsulfone,  
Mizolastine,  Nomifensine,
55% 77% 62%
Logistic Regression - Leave one out testing algorithm
Table 8: Each of the classes named were used to test a logistic regression that was trained on all the 
remaining classes. From left to right column one: Seizurogenic compounds classified as seizurogenic. Column 
two: Non-seizurogenic compounds that were classified as non-seizurogenic. Column three: seizurogenic 
compounds that were classified as non-seizurogenic. Column four: non-seizurogenic compounds classified as 
seizurogenic. Column five: the sensitivity of this modelling approach for seizurogenic compounds. Column six: 
the specificity. Column seven: the overall accuracy.  
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The overall accuracy of the logistic regressions was significantly worse than the 
other two classifiers at 62%, a 9% drop in accuracy compared to NNs and 11% 
relative to SVMs. 
 
SVM and NN performance – Using Randomly selected test and training sets 
SVMs and NNs had similar performance when tested using the leave one out 
approach. As such both were subsequently tested using randomly assigned test 
and training sets. Both algorithms performed well overall with the SVM and NN 
achieving 75% and 85% accuracy respectively.  
The NN appeared to be the most sensitive approach, correctly classifying all 
seizurogenic compounds correctly. However, it performed poorly on non-
seizurogenic compounds achieving only 50% specificity. This means the model 
could be expected to classify non-seizurogenic compounds as seizurogenic 
50% of the time. It is worth noting that although it achieved a very high accuracy 
of 85% this is not truly reflective of the model’s performance as there is a 
Table 9: Top: Classifications of randomly selected test compounds by SVM. Bottom: Classification of randomly selected 
test compounds by NN. From left to right column one: Seizurogenic compounds classified as seizurogenic. Column two: 
Non-seizurogenic compounds that were classified as non-seizurogenic. Column three: seizurogenic compounds that 
were classified as non-seizurogenic. Column four: non-seizurogenic compounds classified as seizurogenic. Column 
five: the sensitivity of this modelling approach for seizurogenic compounds. Column six: the specificity. Column seven: 
the overall accuracy. 
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greater number of seizurogenic compounds than non-seizurogenic compounds. 
Were there as many non-seizurogenic compounds in the test set as 
seizurogenic compounds, and the sensitivity and specificity remained the same, 
the accuracy would drop due to its poor specificity. 
The SVM achieved a sensitivity of 67% and a specificity of 83%, and thus had 
much higher specificity than the neural network while sacrificing a significant 
amount of sensitivity.  
Discussion 
Nomifensine was consistently misclassified across all classifiers tested, when 
using the leave one out approach. Nomifensine misclassification was 
unsurprising given that Nomifensine is similar in pharmacology to a host of 
compounds, such as cocaine, amphetamine and bupropion that are classified 
as ‘seizurogenic’ in the training data. Moreover, Nomifensines peak profile 
clusters well with these compounds during hierarchical clustering (see figure 
10). Interestingly, when training and testing the SVM with randomly selected 
compounds, nomifensine was correctly classified, despite being incorrectly 
classified during leave one out. One possible explanation for this, is that 
cocaine wasn’t used in the training set, as it was randomly selected for the test 
set. Given Nomifensines, close association with cocaine during hierarchical 
clustering (see figure 10) it is possible cocaine’s presence in the training data 
was driving Nomifensines misclassification. This highlights the importance of 
having representative training data, as even a small amount of data can change 
how the model classifies. This is of particular relevance in the case of SVMs, 
because even a single data point can change the position of a hyperplane. 
Comparatively, NNs should be more resilient to small changes in training data. 
Seizurogenic compounds that were misclassified across all the models, during 
the leave one out testing algorithm, included cocaine, gabazine, maprotiline, 
picrotoxin, SNC80 and theophylline. Of these gabazine and picrotoxin have 
extremely low uptake with both averaging less than 2.1% uptake (see table 1).  
It is therefore likely that these compounds don’t reach the concentrations 
required to have substantive seizurogenic effects. Similarly, maprotilines uptake 
is low, especially in the context of the other mixed mechanism antidepressants 
and thus it is possible that maprotiline doesn’t reach adequate concentrations to 
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induce seizure. In the case of SNC80, as previously discussed, it has been 
establish that SNC80 has poor affinity for zebrafish delta opioid receptors (119). 
As such its seizurogenic mechanism is unlikely to be reflected in the animal 
model these analyses are based on. 
All of the compounds consistently misclassified, across the different models 
tested, clustered with non-seizurogenic compounds in the hierarchical clustering 
analyses (see figure 10). It seems that a number of the compounds understood 
to be seizurogenic in the literature are not representative of seizurogenesis in 
this model. This could be due to either: not being present in high enough 
concentrations in zebrafish to elicit a seizurogenic profile or having poor ligand 
receptor affinity. Better training data selection could therefore improve the 
specificity of this approach, but all testing must be used in conjunction with 
compound uptake data which appears to be a specific issue in this experimental 
method. Experimental, modifications could be made such as injecting 
compounds directly into the zebrafish, a subject discussed in greater detail in 
the subsequent chapter.  
Notably, the experimental approach used to generate the data used a variety of 
different concentrations of compounds. It is therefore possible that one or two of 
the concentrations used were not high enough to induce seizure. For example, 
some compounds may be seizurogenic only at the highest concentration and, 
despite correct classification of individual experiments, be considered 
misclassified overall. 
For the classification purposes described, SVMs and NNs perform almost 
identically but both performed better on these data than a logistic regression. 
Logistic regression is ill-suited to the data because a lot of the parameters are 
likely to be highly correlated as some regions of interest can behave very 
similarly in terms of their peak dynamics. In addition, it is suggested that logistic 
regression is only effective when there is a high ratio of experiments to 
parameters and in this case there is not (170).  
During the leave one out test protocol, the SVM and NN algorithms correctly 
classified seizurogenic compounds 70% of the time. Moreover, both algorithms 
correctly classified non-seizurogenic compounds 85% of the time. Given that 
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both algorithms were similarly effective both were selected for further testing 
using randomly selected data sets. 
When trained and tested using the random selection protocol the SVM 
accurately identified 83% of the non-seizurogenic compounds it was tested with, 
however managed just over 67% sensitivity for seizurogenic compounds.  
Despite the relatively poor performance of the SVM in terms of accurately 
identifying seizurogenic compounds it did achieve very high specificity. Given 
that the specificity was high, the final model could to some extent detect 
seizurogenic compounds based on their peak parameters albeit with a relatively 
high false negative rate.  
The NN achieved significantly higher overall accuracy than the SVM due to its 
very high sensitivity. However, it had low specificity which must be taken to 
account if using this model for identification of seizurogenic compounds. The 
low specificity and very high sensitivity are likely symptoms of overfitting 
possibly occurring due to the relatively small amount of training data. Neural 
networks can suffer from overfitting when used on lower sample size, higher 
dimensional data (172).  
Moreover, because there was a smaller amount of non-seizurogenic 
compounds available the high overall accuracy is perhaps not reflective of the 
true efficacy of the models. The imbalance in the test data causes the accuracy 
to be weighted toward the sensitivity of the model and less affected by the 
specificity. Were these analyses to be repeated it would be important to have an 
equal number of seizurogenic and non-seizurogenic compounds in order for the 
models to learn features of both seizurogenic and non-seizurogenic 
compounds. 
Given that the experimental and analytical approaches used here are still very 
preliminary stages there is a huge amount of progress that could still be made. 
It is clear, based on these analyses, that machine learning approaches could 
play a key role in its future development.  
Improvements could made on a number of fronts, including data acquisition, 
training data selection and fine tuning of modelling algorithms. Here I have used 
the inbuilt matlab classification learner tools box to highlight the potential 
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efficacy of these kind of approaches. However, purpose built, and custom 
designed algorithms could yield far superior results. Techniques such as 
unsupervised pre-training of neural networks have been shown to significantly 
improve neural network performance (173). Techniques, such as unsupervised 
learning of deep belief networks, can be used as feature detectors. Feature 
detectors can be used to initialise the weights and biases of neural networks, 
prior to supervised training, to provide powerful classification algorithms. This 
approach has already been utilised in the area of drug discovery to greatly 
improve compound selectivity prediction (174). 
Moreover, machine learning techniques have been utilised in the clinic for 
epilepsy surgery outcome prediction (175) in addition to seizure prediction and 
identification (176). Efforts to create seizure prediction models based on using 
electroencephalography combined with PCA and SVMs resulted in an algorithm 
with 100% sensitivity and over 80% specificity (176). A similar study using PCA 
and SVM achieved similarly impressive results (177). In these cases, EEGs 
were recorded in human subjects and all signals were either from patients 
known to be suffering a seizure or from healthy controls (176,177). By 
comparison the study described here could not guarantee seizure phenotypes 
were present in the fish representing the ‘seizurogenic’ training and test groups. 
Moreover, EEGs have the advantage of extremely high temporal resolution, 
future work on detection of seizurogenic compounds using zebrafish could 
benefit from a comparison of local field potential and calcium imaging peak 
analyses as input data for machine learning algorithms.   
Previous studies have utilised local field potentials recorded in transgenic 
zebrafish with seizure phenotypes to identify anti-epileptic drugs with high 
accuracy (23). Similar analyses could be repeated in zebrafish in addition to 
calcium imaging and both data sets could be combined with the aim of 
identifying potentially seizurogenic compounds. 
 
Chapter 4: Overall discussion and conclusion 
The overall aim of this thesis was to highlight the utility of 4-dimensional 
functional profiling of drugs in zebrafish. It is clear from the analyses performed 
that drugs elicit spatio-temporal patterns of activation in zebrafish specific to 
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their pharmacological properties. It is also clear that these specific spatio-
temporal patterns can be exploited to make elucidations about the properties of 
drugs and that machine learning approaches are well suited for such purposes. 
The clustering analyses showed clear congregations of compounds with similar 
pharmacodynamics, in particular with regards to dopamine and serotonin active 
compounds. This is of particular relevance to anti-depressant drug discovery, 
an area in which novel therapeutics are desperately needed (58). On this basis, 
it seems that compounds with specific pharmacodynamics do seem to elicit 
specific patterns of activation in the zebrafish brain. However, not all 
compounds clustered in a pharmacologically meaningful way, either due to 
bioavailability issues, lack of receptor affinity, or perhaps simply because their 
particular pharmacodynamics did not elicit distinctive patterns. Moreover, it 
should be noted that the cluster analyses do not provide a metric that states 
whether certain compounds are significantly different or not, due to not using 
any form of statistical hypothesis testing. This is due in part to the fact that 
statistical hypothesis testing on data with a large number of experimental 
groups, such as the data in this thesis, encounters problems related to multiple 
comparisons (178). 
As a result it could be argued that it is difficult to draw firm conclusions from the 
clustering dendrogram with regards to the significance of the similarities and 
differences between compounds. Moreover, as clustering was performed on the 
average principal components across the experiments of a compound, the 
clustering doesn’t account for variability between experiments of the same 
compound, which was at times significant.  
Despite the limitations related to clustering, this approach allows users to gain 
an understanding of the data set and illustrates how the different experimental 
groups relate to one another. This is highly useful for step and in this case 
showed that there were some strong similarities between compounds with 
similar pharmacologies, relative to other pharmacologically distinct compounds. 
And it is this concept that underpinned the rationale behind the application of 
machine learning to the data set.   
It is clear that machine learning techniques can be applied effectively to 4-
dimensional zebrafish brain activity data for the identification of potentially 
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seizurogenic compounds. The tests showed fairly high accuracy, sensitivity and 
specificity in the classifiers chosen for testing. The analyses showed that either 
SVMs or NNs could prove useful for compound classification purposes, 
however neural networks could benefit from a larger data set. Classifiers, such 
as the machine learning techniques described here, have a huge amount of 
potential utility in the pharmaceutical industry due to their ease of application to 
new data sets and new classification problems. It is clear from the analyses 
presented here, that machine learning tools provide a powerful and replicable 
approach for making elucidations about drug properties. 
However, in the context of this study, there are a number of limitations with 
regards to the machine learning approaches that should be reiterated. SVMs 
are sensitive to anomalous data, so if one compound classified as seizurogenic 
in the training data is actually non-seizurogenic, due to experimental 
constraints, this is likely to have a significant effect on the how the algorithm 
classifies test data. Moreover, neural networks are likely to perform poorly if not 
enough data is available because the ratio of the number of experiments 
relative to the number of parameters needs to be reasonably high (179).  
When designing the analytical approaches used during this project there were a 
number of decisions to make. These different analytical choices all have 
different advantages and disadvantages worth noting. As discussed, the spatial 
resolution of light sheet microscopy is very high, to reduce the computational 
intensity of the analyses and to put analyses into a more biologically relevant 
context, ROIs were defined using a standardised 3D anatomical map of the 
larval zebrafish brain (4,42). The atlas in question utilised 6dpf zebrafish larvae 
to generate the three-dimensional anatomical atlas utilised for ROI selection. 
The zebrafish larva used for this study were 4dpf and as such could have a 
considerably different anatomical make up to the zebrafish used to generate 
this map. This could cause voxels from distinct functional areas to be averaged 
together with the results being an output of time series that misses large chunks 
of informative data. 
Alternatives, such as spatially constrained spectral clustering, an algorithm 
developed for use in functional MRI, utilises the functional similarities of voxels 
to generate ROIs, thus generating ROIs based on the functional make up of 
individual fish (46). However, such data driven ROI selection approaches also 
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have problems, such as lack of consistency in ROI selection making between 
subject valid comparisons of ROIs difficult.  
Another alternative could simply be to use individual voxels however the varying 
sizes of fish may cause the number of voxels present within the animal itself to 
vary, again making between subject comparisons difficult. This is therefore an 
ongoing challenge. 
An additional important analytical decision worth noting was the choice to use 
Pearson’s correlation coefficient for pairwise comparisons of ROIs during 
functional connectivity analysis. As mentioned Pearsons correlation coefficient 
was chosen because it is simple to understand and implement while 
considering the amplitude and phase of any underlying oscillatory activity. 
However other approaches, such as cross correlation, coherence and grangers 
causality, may be more suitable in future if experimental approaches or 
analytical approaches are modified.  
Coherence is a measure of the level of similarity in frequency content and has 
been utilised in electrophysiology and magnetoencephalography due to its 
capability to deal with very high temporal frequency data (180). This particular 
approach is not applicable to this study as the temporal resolution was simply 
not high enough. Were there a change in experiment approaches that caused a 
significant increase in temporal resolution coherence would be a potentially 
useful tool.  
Lagged cross correlation is also a useful measure of similarity as it can be 
utilised to take into the ‘lag’ between signals. This measure is useful in 
situations where there is a slight time delay between signals as it can be used 
to account for this lag when performing analyses. This approach was tested 
during the analyses conducted however it was deemed that the measurements 
of calcium transients in this study were too slow for lag correction to have be of 
any real utility. As such Pearson’s correlation coefficient was deemed a 
preferable option. Were a different transgenic fish line used, with faster 
measures of calcium transients, cross correlation may provide a superior 
measure of functional connectivity. The calcium transient utilised for this study, 
GCaMP6s is considered the most sensitive for changes in calcium levels 
however GCaMP6f has a considerably higher rise and decay time allowing for 
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the detection of calcium transients with higher temporal resolution (34). Given 
that the temporal resolution of LSM is low it made sense in this context to utilise 
the slower more sensitive sensor GCaMP6s. 
The combination of LSM and zebrafish with genetically encoded calcium 
indicators is relatively new experimental approach. The advantages this method 
allows experimenters, wishing to study whole brain network dynamics, are 
significant. LSM allows imaging of the entire zebrafish brain at sub-single cell 
resolution and with significantly improved temporal resolution over equivalent 
scanning microscopes (181). However, despite this advantage, there are a 
number of limitations to be considered. Light sheet microscopes still have low 
temporal resolution, relative to electrophysiological recordings, particularly when 
imaging a large number of z-planes, typically taking just under two seconds for 
ten z-stacks (4). This temporal resolution is significantly lower than the potential 
temporal resolution available using GCaMP sensors, which are capable of 
temporal resolution in the millisecond range (182). However the calcium sensor 
for this study (GCaMP6s) is a slower acting calcium sensor due to the slow rise 
and fall rate of the dye (183), which means LSM has more than adequate 
temporal resolution. 
Therefore, a potential alteration to the experimental setup, worth investigating is 
the temporal resolution of LSM. As mentioned, when utilising LSM it is a trade-
off between the volumetric coverage achieved and the temporal resolution. In 
future, studies could focus on more specific brain regions at significantly higher 
temporal resolution, utilising GCaMP6f sensors and measuring functional 
connectivity with cross correlation to provide more complete temporal coverage 
of specific regions.  
While the temporal resolution of LSM is relatively low, it has extremely high 
spatial resolution and can been used for imaging at cellular resolution (181). 
High spatial resolution has the potential to be particularly useful when 
attempting to classify neuroactive compounds based on brain activity because 
often specific neurotransmitters are found in specific brain areas 
(113,116,184,185). This seems to be particularly true of the serotonergic and 
dopaminergic systems and may explain why serotonergic (113,116) and 
dopaminergic compounds (116) clustered in close proximity during analyses 
(see figures 8 and 9).   
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In this study there were a number of issues pertaining to bioavailability. This is 
because, fish were exposed to compounds dissolved in water and in order for 
compounds to make it into the zebrafish CNS they need to be absorbed through 
external tissues which may be impossible or difficult in the case of certain 
compounds. This meant a number of compounds being absorbed only in small 
quantities (see table 1).  In addition to absorption issues, it is clear drugs that 
are insoluble are going to be very difficult to test using this approach. It is 
therefore necessary, if using this approach as an assay, to perform 
bioavailability assays to ensure compound performance is related to its 
pharmacological properties, as opposed to its absorption into the zebrafish 
CNS. Alternatively, it is possible to inject compounds into the cardinal vein of 
zebrafish embryos which guarantees uptake into the zebrafish body and thus 
maybe be a preferable technique for this assay in future.  
Among the considerable advantages, of using zebrafish, is that they have a 
blood brain barrier homologous with higher invertebrates (186). This poses a 
significant benefit over in vitro models and in vivo models where drugs are 
injected though a cannula directly into brain tissue, because it provides a model 
that gives insight into the relevant pharmacokinetics of compounds in addition to 
the pharmacodynamics. While worth mentioning, this is not hugely relevant to 
this study as the zebrafish blood brain barrier isn’t fully developed at 4dpf and 
therefore isn’t likely to provide useful insight into pharmacokinetics at this 
developmental stage (187). It is possible future studies could use zebrafish at 
later developmental stages that do take advantage of this useful aspect of 
zebrafish physiology. However there are a number of problems associated with 
using zebrafish at latter stages chief among which are the ethical considerations 
of using neuromuscular blocker in protected life stage fish. There are number of 
alternative methods for ‘trapping’ zebrafish for imaging including using 
hydrodynamic force to hold zebrafish in specifically designed microfluidic 
channels (35). This approach confers a number of other advantages including 
the ability to keep zebrafish in water (as opposed to agarose) and the ability to 
perform ‘wash on wash off’ compound exposure.  
Another potential problem associated with using later stage zebrafish is the 
increased brain volume may cause issues with brain coverage. The obvious 
solution is to reduce magnification resulting in reduced resolution. This would be 
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of little consequence, in the x and y planes set up described here, as the brain 
is divided into anatomically defined regions during image analysis, as such the 
full resolution isn’t utilised. However as the brain gets larger it requires more z-
stacks (that is to say images taken in different z-planes) to provide adequate 
coverage and this reduces temporal resolution. Loss of temporal resolution 
would potentially cause recordings to miss some dynamic brain activity, as such 
it is unlikely that functional full brain coverage would be ideal past 7 day post 
fertilisation. 
A notable issue, relevant to this study, is the poor affinity of SNC80 for zebrafish 
delta opioid receptors (119). This issue is chiefly notable because it provides an 
example of where brain receptors in zebrafish are no longer adequately 
homologous with humans to bind compounds with acute effects on human 
tissues. This would be of particular concern, in this case, as SNC80 is a 
compound with well characterised seizurogenic properties (156). Given that 
SNC80 was among the compounds most consistently misclassified or 
misplaced during analyses, it is plausible other compounds may produce false 
negative results for seizurogenic properties, not due to flaws in the analytical or 
experimental method, but due to the physiology of the zebrafish itself.  
However, it should be acknowledged that SNC80 is in contradiction to the 
broader trend. Zebrafish are generally considered to be excellent models for 
studying the central opioid and endocannabinoid systems and have just over 
60% pairwise alignment homology scores for both the opioid and 
endocannabinoid systems when compared with humans (188). Moreover, 
zebrafish have shown to be highly sensitive to antidepressants (189), a fact 
corroborated by the analyses describe here (see figures 8 and 9). More 
generally speaking, zebrafish have orthologous genes for approximately 70% of 
the human genome; zebrafish also have equivalent genes for 84% of human 
genes associated with disease (190).  
The high level of homology with higher invertebrates and genetic malleability of 
zebrafish means there are many different transgenic zebrafish models of human 
disease including: depression (21), anxiety (191), epilepsy (192) and serotonin 
syndrome (193). Future work could utilise transgenic zebrafish models with 
spontaneous seizure phenotypes to train classification learners to recognise 
seizure and thus identify seizurogenic compounds. A similar approach could be 
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utilised using serotonin syndrome mutants to identify antidepressant 
compounds. The zebrafish as a model organism provides a huge number of 
potential future directions for this project. 
Among the more prominent experimental limitations present in this study is the 
lack of a within experiment control. The zebrafish analysed here are relatively 
heterogeneous and the lack of drug free baseline period for each fish makes 
normalisation of experiments difficult. Lack of an adequate normalisation 
process makes between subject comparisons in heterogeneous data unreliable. 
This is of particular relevance with regards to differences in overall brain activity 
induced by compounds. Because control fish can vary significantly in their 
overall fluorescent intensity, identifying if compounds are increasing overall 
fluorescent intensity and thus brain activity is very difficult as there is no drug 
free baseline period for each fish with which to generate a relative measure of 
fluorescent intensity (and thus brain activity). The introduction of a drug free 
baseline period for each experiment would therefore allow better 
characterisation of the changes in overall brain activity induced by particular 
drug classes and would therefore add a whole new dimension of informative 
data into the analytical process. This could prove to be of particular relevance to 
the seizurogenic potential of compounds as PTZ, a well categorised 
seizurogenic compound (194), has been demonstrated to rapidly and 
significantly increase baseline activity (36). 
Introducing a drug free baseline period has potential downsides. Some 
compounds utilised for these analyse require long exposure times. Long 
exposure times would require fish to be imaged for a very long time, extended 
period in agar tend to cause the health of fish to deteriorate which would 
introduce an unwanted confound into the analyses. As such it would be 
logistically difficult to perform analyses on compounds with long exposure times 
such as Rolipram, which requires a 24-hour exposure regimen (see table 1). 
Despite the limitations, it is clear from the analyses that the experimental and 
analytical approaches described here are highly useful for profiling drugs. As 
discussed previously, there are a plethora of advantages to using zebrafish and 
as such the methodologies described here are highly applicable for use in 
industry. There are also a number of methodological alterations that have the 
potential to improve these approaches, both experimentally and analytically. 
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Overall, it is clear from the works described here, that the future is bright for the 
zebrafish in pharmaceutical research.  
 
Conclusions 
Transgenic zebrafish are a powerful tool for assessing the effects of drugs on 
the central nervous system. When combined with genetically encoded calcium 
sensors and light sheet microscopy, zebrafish provide a 4-dimensional model of 
brain networks with extremely high spatial resolution and modest temporal 
resolution.  
Clustering analysis revealed that spatial patterns of activity as reflected by their 
spatially specific peak parameters and functional connectivity values are 
specific to the pharmacodynamics of certain compounds. It is clear that 
dopamine and serotonin active compounds in particular elicit specific spatio-
temporal patterns of activity. Further analysis also showed strong clustering of 
seizurogenic compounds, in particular when clustered based ion their peak 
parameters. Further analysis showed that peak parameters can be used to train 
classification learners such as SVMs and NNs to produce models that can 
accurately discriminate between seizurogenic and non-seizurogenic 
compounds.  
A number of experimental modifications could be utilised in future work, such as 
using GCaMP sensors with faster activing dyes (e.g. GCaMP6f), introducing 
within experiment controls and reducing the number of z-slices to increase 
temporal resolution (at the expense of brain coverage).  
Future directions, in terms of analysis, could focus on utilising different ROI 
selection approaches, such as spatially constrained spectral clustering and 
using unsupervised learning algorithms, such as deep belief networks, for 
feature selection prior to neural network modelling. In addition, when choosing 
compounds for the training and testing of classification learners stringent 
thresholds for bioavailability and receptor affinity could be implemented that 
improve the performance of models. 
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